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ABSTRACT OF THE DISSERTATION
Granulocyte-Colony Stimulating Factor Reprograms the Bone Marrow Microenvironment to
Suppress B Lymphopoiesis
by
Ryan Brent Day
Doctor of Philosophy in Biology & Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2016
Professor Daniel Link, Chairperson
The production of hematopoietic cells in the bone marrow is tightly and dynamically regulated in
response to environmental stimuli. In response to infection, the bone marrow increases
granulopoiesis at the expense of lymphopoiesis. The mechanisms mediating this shift are poorly
understood. We show that treatment with granulocyte-colony stimulating factor (G-CSF), which
is often induced during infection, results in marked decline of B lymphocytes at multiple stages
of bone marrow B cell development. Transgenic mouse models show that G-CSF acts in a noncell intrinsic fashion through cells of the monocyte-macrophage lineage to suppress B
lymphopoiesis by downregulating important B trophic factors including CXCL12, KIT ligand,
FLT3 ligand, interleukin-6, interleukin-7, IGF-1, and BAFF, resulting in B cell mobilization and
apoptosis. G-CSF reprograms CXCL12-abundant reticular (CAR) cells, bipotent adipogenicosteogenic stromal cells that are a key component of the B cell niche, increasing osteogenic
potential and downregulating the production of CXCL12, interleukin-7, and KIT ligand. G-CSF
also decreases osteoblast number, disrupting an additional B niche population and source of key
B cell developmental cytokines. These data show that G-CSF reprograms bone marrow stromal
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cells to alter the bone marrow microenvironment to actively suppress B lymphopoiesis. To
further explore the role of stromal cell-derived CXCL12 in B lymphopoiesis, we examined mice
in which Cxcl12 was conditionally deleted in different stromal cell populations. Deletion of
Cxcl12 using Dmp1-Cre (targeting osteolineage cells) does not disrupt bone marrow B
lymphopoiesis. Deletion of Cxcl12 using OC-Cre (targeting osteolineage cells and vascular
smooth muscle cells) results in an isolated loss of mature naïve B cells in the bone marrow due to
a homing defect following peripheral maturation. Deletion of Cxcl12 using Osx-Cre (targeting
CAR cells) results in an early loss of bone marrow B cells beginning with pre-pro-B cells.
Deletion of Cxcl12 using Prx1-Cre (targeting mesenchymal progenitors) results in severe
suppression of B lymphopoiesis, including a loss of CLP, the upstream progenitor of B, T, and
NK cells. These data suggest that CXCL12 from different stromal cell populations in the bone
marrow regulates distinct stages of B lymphopoiesis.

xi

CHAPTER 1: INTRODUCTION TO THE BONE MARROW MICROENVIRONMENT
AND B LYMPHOPOIESIS

The production of mature blood cells from uncommitted progenitors in the bone marrow
is a tightly regulated process that is highly responsive to environmental stimuli. Hematopoietic
differentiation occurs via a hierarchical pattern of lineage commitments, beginning with an
uncommitted hematopoietic stem cell (HSC) with the potential to give rise to any type of
hematopoietic cell. HSCs give rise to multipotent progenitors, which in turn produce lineagerestricted progenitors that ultimately give rise to mature blood cells1. The production of mature
blood cells from progenitor populations within the bone marrow is regulated by the bone marrow
microenvironment or niche, a specialized group of adjacent cells, extracellular matrix, and
secreted factors that regulate proliferation and differentiation of developing cells. Different
niches have been postulated to exist for different hematopoietic lineages as well as for different
stages of differentiation within a single lineage2,3. Dysregulation of the normal maturation of
hematopoietic cells in the bone marrow is associated with a variety of pathologic conditions.
Better understanding how the bone marrow microenvironment regulates the proliferation and
differentiation of hematopoietic cell types is therefore important to understanding how
hematopoietic diseases arise and can be treated.
One of the earliest fate decisions made by an uncommitted hematopoietic progenitor is
commitment to either the myeloid lineage or the lymphoid lineage. The earliest committed
myeloid cell is known as the common myeloid progenitor and is capable of giving rise to red
blood cells, platelets, monocytes, macrophages, osteoclasts, dendritic cells, and granulocytes 1.
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The most primitive lymphoid-committed cells is known as the common lymphoid progenitor
(CLP), which is capable of producing B cells, T cells, natural killer cells, and dendritic cells4,5.
The cells of the B lineage are part of the adaptive immune system and give rise to
antibody-secreting cells. B cell development occurs in both the bone marrow and peripheral
lymphoid organs through a well-described stepwise progression of stages that can be identified
based on surface marker expression (Figure 1.1). In the bone marrow, the CLP gives rise to the B
lymphoid progenitor (BLP), the earliest known B-committed cell6. Pre-pro-B cells, also known
as Fraction A cells, are derived from the BLP and predominately retain germline expression of
immunoglobulin genes. Early pro-B/Fraction B cells have begun the process of heavy
immunoglobulin chain (IgH) rearrangement, a process that is completed in late pro-B/Fraction C
cells. B cells that have successfully rearranged IgH express the pre-B cell receptor (pre-BCR) on
the cell surface. Signaling through the pre-BCR directs light chain recombination in preB/Fraction D cells. Cells that successfully rearrange light chain immunoglobulin are known as
immature/Fraction E cells and express cell surface IgM, composed of a complex of rearranged
heavy and light immunoglobulin chains. Most immature B cells migrate from the bone marrow
to the spleen where they undergo additional maturation into mature naïve B/Fraction F cells
expressing both IgM and IgD on the cell surface7–10, though some may complete maturation in
the bone marrow without transiting to the spleen11. Mature naïve B cells recirculate between the
bone marrow and peripheral lymphoid organs. Upon exposure to a recognized antigen, they
undergo additional stages of maturation in the periphery and can home back to the bone marrow
as mature antibody-secreting plasma cells9,10.
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1.1. Key Cytokines Regulating Bone Marrow B Lymphopoiesis
1.1.1. CXCL12
B cell development in the bone marrow is regulated in part via soluble factors produced
by the bone marrow microenvironment. CXCL12, also known as stromal-derived factor 1 (SDF1) or pre-B growth stimulating factor, is a chemokine important for B lymphopoiesis. CXCL12
was originally isolated from stromal cell lines as a factor stimulating B cell development in in
vitro cultures12. Mice deficient for CXCL12 are perinatal lethal, and fetal livers from these mice
have reduced number of B cells and low CFU-pre-B activity13. Similarly, mice lacking the
primary receptor for CXCL12, CXCR4, have an early defect in B lymphopoiesis, with a
reduction in pre-pro-B cell number and reduced numbers of Lin- IL-7R+ KITlow Scalow cells, a
compartment enriched for CLPs and BLPs14–16. Transgenic mice expressing an intracellular
form of CXCL12, expected to inhibit CXCL12-CXCR4 signaling by sequestering CXCR4 in
intracellular compartments, show decreased B cell number beginning with the pro-B stage, while
overexpression of extracellular CXCL12 increases B cell number, demonstrating a requirement
for extracellular CXCL12-CXCR4 signaling for normal B cell development 17.
CXCL12-deficient fetal liver cells transplanted into wild type recipients are capable of
reconstituting the hematopoietic system, including B lymphopoiesis, demonstrating that
CXCL12 from the non-transplantable stromal compartment, not from hematopoietic cells, is
required for B cell development. Conversely, serial transplants from mice reconstituted with
CXCR4-deficient fetal liver cells show reduced numbers of B cell progenitors in the bone
marrow, indicating that CXCR4 signaling within B cells is required for efficient B
lymphopoiesis. In these mice, the number of B cells in peripheral organs are only mildly
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reduced, showing that the CXCL12-CXCR4 axis plays at most a minor role in maintenance of
the peripheral B cell pool18.
In addition to its role in enhancing B cell proliferation, CXCL12 is known to serve as
potent chemoattractant for a variety of cell types, and several lines of evidence suggest that part
of the B cell phenotype in CXCL12 or CXCR4 knockout mice is due to a failure of B cell
trafficking. Mice deficient for either CXCL12 or CXCR4 have hypocellular bone marrow 14,
suggesting a defect in the migration of hematopoietic cells from the fetal liver to the bone
marrow. Cxcr4 knockout mice have a low number of pro-B cells in the fetal liver and an elevated
number in the peripheral blood, suggesting a defect in the retention of developing B cells.
Transplant of CXCR4-deficient fetal liver cells into wild type mice results in a reduced
percentage of B cells in the bone marrow relative to wild type controls and an increase in IgMnegative B cells detectable in the peripheral blood, indicating inefficient retention of developing
precursors19. Use of a Cd19-Cre transgene to conditionally delete Cxcr4 at the pro-B stage of
development also shows a loss of bone marrow tropism in B cells, with mature B cells
preferentially locating to the periphery and IgM-negative B cells detected in the spleen. Splenic
IgM-negative B cells display an elevated rate of apoptosis, indicating that the bone marrow
microenvironment is critical for developing B cell survival. Immunization assays show reduced
homing of antigen-specific plasma cells to the bone marrow at early post-exposure time points
but normal levels at 90 days, indicating that CXCL12-CXCR4 signaling plays a role in shortterm plasma cell homing but redundant pathways exist for long-term homing20. Further evidence
for the importance of the bone marrow microenvironment for developing B cell survival comes
from mice deficient in the S1P1R adhesion receptor, which show a premature release of B cells
from the bone marrow and increased apoptosis in the periphery21.
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Mutations in CXCR4 are known to play a role in human diseases, including diseases with
perturbations in B cell development or function. WHIM syndrome is a genetic disorder named
for its common clinical manifestations: warts, hypogammaglobulinemia, infections, and
myelokathexis (retention of mature neutrophils in the bone marrow). Most patients with WHIM
syndrome have a mutation in the carboxy-terminus of CXCR4 that results in premature
truncation, believed to enhance CXCL12-CXCR4 signaling by preventing receptor
internalization and downregulation22–28. Since CXCR4 signaling is known to promote retention
of cells in the bone marrow, it has been hypothesized that hyperactive CXCR4 signaling
sequesters B cells in the bone marrow, deranging normal B lymphopoiesis and resulting in
hypogammaglobulinemia. B cell lymphopenia is common in patients with WHIM syndrome29,
and a mouse model in which one WHIM mutation is knocked-in to the endogenous CXCR4
locus recapitulates peripheral lymphopenia and reduced or absent B cell follicles in secondary
lymphoid tissues. Bone marrow sequestration may not be the complete explanation for decreased
peripheral B cells, however, since WHIM mice also show decreased pro-B/pre-B cells and
immature B cells in the bone marrow, suggesting that enhanced CXCR4 signaling impairs early
stages of B lymphopoiesis30. An activating mutation in CXCR4 found in WHIM patients is also
highly recurrent in some B cell malignancies, including 28.2% of lymphoplasmacytic lymphoma
cases and 20% of IgM-MGUS cases. In a murine model of lymphoplasmacytic lymphoma the
mutation was found to enhance lymphoma proliferation, dissemination to the bone marrow and
other organs, and chemotherapy resistance31, indicating that CXCL12-CXCR4 signaling may be
an attractive target when treating diseases featuring perturbed B cell development.
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1.1.2. Interleukin-7
Interleukin-7 was originally identified as a supportive factor for B cell cultures in vitro32.
Mice deficient for IL-7 have reduced B lymphocyte number in the bone marrow as well as in the
peripheral blood and secondary lymphoid organs. B cells that are produced appear to have
normal function, however, suggesting that IL-7 is required for efficient B cell development but
may be dispensable for B cell function33. Consistent with the Il7 knockout mice, mice deficient
for a component of the IL-7 receptor (IL-7R), IL-7R, have a reduction in cellularity in
lymphoid organs due to defects in B and T lymphocytes. In vivo, pro-B cells are the earliest stage
of B lymphopoiesis where number is reduced, suggesting that IL-7 signaling is critical for the
pre-pro-B to pro-B transition34. However, other evidence suggests that IL-7 may be important at
earlier stages of B lymphopoiesis. CLPs express IL-7R but have normal numbers based on
surface phenotype in both IL-7 and IL-7R knockout mice35. Upon transplant into wild type
mice, however, CLPs from mice lacking IL-7 show reduced contribution to B lymphopoiesis,
suggesting that IL-7 signaling at the CLP stage is required for full B cell potential36. Similarly, in
Il7r knockouts pre-pro-B cell number is normal but transcription factors important for further B
cell differentiation are absent or reduced relative to wild type pre-pro-B cells35. Furthermore,
pre-pro-B cells derived from IL-7-deficient mice are less efficient at producing B cells after
transplant into wild type recipients compared to pre-pro-B cells derived from wild type
animals37, indicating IL-7 is required at early stages of B cell development in order for normal B
cell differentiation to occur.
In addition to controlling B cell differentiation, IL-7 is important in the proliferation and
survival of developing B cells. In in vitro culture, IL-7 promotes pro-B proliferation38, and B
cells derived from IL-7R mice fail to proliferate in in vitro culture34. IL-7R is also known to
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deliver survival signals to developing B cells. IL-7 signaling plays a role in maintaining genomic
integrity by inhibiting immunoglobulin rearrangement during times of B cell proliferation,
preventing massive genetic instability and apoptosis as pro-B cells are rearranging
immunoglobulin heavy chain39–44. IL-7 signaling appears to be dispensable for human B
lymphopoiesis, however, since humans with mutations in the c gene, an essential component of
IL-7R, or Jak3, a downstream signaling molecule, have normal B cell number 45,46.
1.1.3. FLT3 ligand
The receptor FMS-Related Tyrosine Kinase 3 (FLT3, also known as FLK2) and its ligand
FLT3L are required for normal B cell development. Mice deficient for FLT3 have normal
splenic cellularity and normal myeloid development in the bone marrow but decreased bone
marrow B cell number. Pre-pro-B and pro-B cell number is severely reduced, pre-B number is
slightly decreased, and mature naïve B cell number is normal, indicating that FLT3 signaling is
important for early stages of B cell development but non-essential for later stages. CFU-pre-B
assays show decreased numbers of B cell progenitors, consistent with a defect in early B
lymphopoiesis47. Similarly, mice deficient for FLT3L have a reduction in bone marrow
cellularity due in part to decreased B cells and a reduction in CFU-pre-B in both frequency and
absolute number. As in the receptor knockout, early stages of B cells in the bone marrow (pro-B
and pre-B) are most severely affected, while mature B cells are less severely affected.
Circulating B cells in the peripheral blood are reduced but normal in function48. Later studies in
both Flt3 and Flt3l knockout mice detected a loss of CLPs, indicating that FLT3 signaling is
important in the earliest stages of lymphopoiesis. A competitive transplant where FLT3Ldeficient bone marrow was competitively transplanted against wild type bone marrow showed
that FLT3L knockout cells contributed equally to all lineages except B cells, suggesting that
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progenitors developing in a FLT3L-deficient environment have a permanent reduction in B cell
competency49.
1.1.4. KIT ligand
KIT ligand (KITL, also known as stem cell factor) and its receptor, KIT, have been found
to play a role in B cell development in adult mice. Mice with a hypomorphic kit allele have
normal levels of mature B cells in the periphery but reductions in late pro-B, pre-B, and
immature B cells in the bone marrow. The defect in B lymphopoiesis was traced back to the CLP
stage50, suggesting that KIT signaling is required for early stages of B cell development but not
maintenance of mature B cell number.
1.1.5. BAFF
B cell activating factor (BAFF) and its receptor BAFF-R play a critical role in later stages
of B cell development. Baff knockout mice show low levels of circulating immunoglobulins,
small peripheral lymphoid organs, and decreased numbers of B cells in the periphery. Early
stages of bone marrow B lymphopoiesis appear roughly normal, but splenic lymphopoiesis
shows a block in B cell development from the immature B to mature naïve B cell stage of
development. A similar defect is observed in mice lacking BAFF-R51. The observation that some
maturation of immature B cells to mature naïve B cells occurs in the bone marrow suggests that
there may be a role for BAFF in the bone marrow in addition to its role in splenic
lymphopoiesis11.
1.1.6. Interleukin-6
The cytokine interleukin-6 (IL-6) has been most extensively studied in its effects on
peripheral B cell development. IL-6 is known to induce differentiation of mature B cells into
plasma cells, and to enhance antibody secretion from plasma cells 52,53. Evidence also exists that
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IL-6 induces proliferation of pre-B cells in vitro54, indicating that it may play a role in enhancing
bone marrow B lymphopoiesis as well.
1.1.7. RANK ligand
Receptor Activator of NF-kB (RANK) and its ligand RANK ligand (RANKL) are most
well-known for the role they play in osteoclast development, but they also play an important role
in bone marrow B lymphopoiesis. Rankl-/- mice show decreased immature B and mature naïve B
number in the spleen, but bone marrow B lymphopoiesis is difficult to assess due to extensive
osteopetrosis. Transplant of RANKL-deficient hematopoietic cells into Rag1-/- mice, deficient in
the production of lymphocytes, results in a block in B lymphopoiesis at the pro-B to pre-B
transition55. Similarly, Rank-/- mice have a reduction in splenic mature naïve B cell number 56,
suggesting that RANKL-RANK signaling is important for both bone marrow and peripheral B
cell development.
1.1.8. Insulin-like growth factor 1
The cytokine insulin-like growth factor 1 (IGF-1) has also been reported to play a role in
B lymphopoiesis. In vitro, addition of IGF-1 to murine B cell cultures enhances the
differentiation of pro-B cells to pre-B cells, and inhibition of IGF-1 production in stromal cells
impairs their ability to induce pro-B to pre-B differentiation57. Similar results were found in an in
vitro assay with human cells58. Continuous infusion of IGF-1 into mice has also been shown to
increase bone marrow B cell number59. Study of IGF-binding proteins (IGFBPs), carrier proteins
that can enhance or inhibit IGF-1 signaling, shows that IGFPBP3 attenuates pro-B development
while IGFBP-6 stimulates pro-B differentiation, providing further evidence that IGF-1 signaling
can promote B cell development 58.
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1.1.9. Cooperative interactions
Cooperative interactions between B trophic cytokines demonstrate that the coordinated
expression of multiple cytokines in the microenvironment can play an important role in B
lymphopoiesis. In vitro IL-7 and KITL promote CFU-pre-B colony formation more efficiently
than either alone60. Insulin-Like Growth Factor 1 (IGF-1) is also known to synergize with IL-7 to
promote B cell expansion and pre-B maturation61. Conversely, while mice deficient for either
FLT3L or IL-7Rhave similar phenotypes, mice deficient for both have a more severe
phenotype than either alone, including a more severe reduction in peripheral lymphoid organ size
and an almost complete absence of functional B cells62. Similarly, mice deficient for both FLT3
and KIT have a more severe phenotype than either single mutant 47.
1.2. B cell niche populations
In the bone marrow, B lymphopoiesis is guided not only by secreted cytokines but also by
cell-cell interactions between developing B cells and other hematopoietic or stromal populations.
There are multiple lines of evidence suggesting that B cell niche populations exist and that B
lymphopoiesis is altered if normal niche function is disrupted, but how niche populations
regulate B cell development is unclear. The most popular model in the field is that B cells
interact with different niche populations at different stages of B cell development, and that B
cells move from one niche to another as they develop63,64 (Figure 1.2). In this model, it is
generally assumed that different niche cells make specific factors that are required for specific
stages of B cell development. Other models are also plausible, however. It is possible that B cells
remain relatively static in the bone marrow, continuously in close proximity to a small number of
niche cells that provide all of the factors required for B lymphopoiesis. Such factors could be
regulated temporally, with niche cells altering their transcriptional profile as B cell requirements
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change, or niche cells could maintain a relatively constant production of B trophic factors, with
B cell sensitivity to these secreted factors changing as B cells mature. While the niche is
generally considered to consist of cells in direct contact with a developing B cell, it is possible
that factors secreted by distant cells regulate some aspects of B cell development. These models
are not necessarily mutually exclusive; it is possible that some elements from each model are
true for specific niche populations, B cell populations, or soluble factors. Further study of the B
cell microenvironment will be needed to resolve these questions.
1.2.1.

Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stromal cells in the bone marrow,

classically defined as having the ability to differentiate into osteoblasts, chondrocytes, and
adipocytes in a fibroblastic colony forming unit (CFU-F) assay. The extent to which the CFU-F
assay tests true MSC potential is unclear, since true bone marrow MSCs may give rise to more
stromal cell populations than this limited set, and multipotent populations that are not MSCs may
also give rise to CFU-F. In vivo, MSCs are considered to be rare perivascular cells, but in situ
observation of them has been elusive, due in part to a lack of consensus on how to best identify
MSCs. Various markers have been proposed to identify MSCs in vivo in bone marrow, including
combinations of PDGFR, PDGFR, CD51, and Sca; alpha smooth muscle actin; and the
Nestin-Gfp transgene65–69. A lineage mapping model using Prx1-Cre, a transcription factor
activated in limb bud mesenchyme, to activate a fluorescent reporter has also been reported to
identify a rare cell highly enriched for CFU-F activity70. While developing B cells are not known
to interact with MSCs in the bone marrow, putative MSCs have been reported to make several
cytokines important in B cell development, including CXCL12, KITL, and IL-768,70–73.
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1.2.2. CXCL12-abundant reticular cells
CXCL12-abundant reticular (CAR) cells were identified by a knock-in of Gfp into the
Cxcl12 locus. CAR cells are defined as CD45-negative Ter119-negative CD31-negative stromal
cells expressing high levels of GFP. They have a characteristic reticular morphology, with long
processes extending throughout the bone marrow, and are predominantly perivascular in
location63. CAR cells produce high levels of CXCL12 and are considered to be the major source
of CXCL12 in the bone marrow74. They also produce high levels of KITL72,74.
CAR cells have been reported to be in direct contact with several hematopoietic
populations, including pre-pro-B cells63, consistent with a role for CXCL12 and KITL in early B
cell development. A diphtheria toxin-ablation model points to a role for CAR cells in early stages
of B cell development, since CAR cell ablation is rapidly followed by a loss of CLP and
decreased proliferation and increased apoptosis of pro-B cells. HSCs also show increased
commitment to the myeloid lineage, indicating that CAR cells may play a role in maintaining
lymphopoietic potential. However, this model is complicated by the fact that the mice die within
5 days with severe liver necrosis74, suggesting that CAR cell ablation has severe organism-wide
effects and that the observed changes may be secondary to other effects rather than directly due
to loss of CAR cells.
CAR cells were originally described as bipotent adipogenic-osteogenic cells, expressing
both osteogenic and adipogenic transcription factors at the single cell level74. Lineage mapping
using Osterix-Cre to target CAR cells results in fluorescent reporter activity in both CAR cells
and osteoblasts, consistent with the hypothesis that CAR cells are osteoprogenitors 70. However,
Leptin-receptor-Cre (Lepr-Cre) efficiently targets CAR cells and adipocytes but not osteoblasts,
casting doubt on the idea of CAR cells as osteoprogenitors73. This discrepancy may be resolved
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by two recent papers that suggest that CAR cells give rise to osteoprogenitors in adult mice but
not young mice. Primordial CAR cells are first detectable at E16.5 but express low levels of
genes associated with CAR cells in adult mice75. Lepr-Cre-targeted cells, the vast majority of
which are likely CAR cells, are rare at E19.5 and common in the metaphysis but not the
diaphysis at P0.5, suggesting that CAR cells arise late in fetal development and are rare for much
of early bone marrow development. By 2 months of age Lepr-Cre-targeted cells are common in
both the metaphysis and diaphysis. Based on lineage mapping they have little to no contribution
to chondrocytes or osteoblasts in 2 month old mice but have increasing contribution to
osteoblasts with age. CFU-F assays, ossicle formation assays, sublethal irradiation, intrafemoral
injection, and fracture models all provide evidence that Lepr-Cre-targeted cells from adult mice
have osteogenic, chondrogenic, and adipogenic potential71. Collectively, these data suggest that
Lepr-Cre-targeted CAR cells may contain an MSC-like population in adult mice, but that
chondrocytes and osteoblasts in young mice derive from a different progenitor. Since the
progenitor cell for CAR cells is currently unknown, it is also possible that Lepr-Cre-targeted
CAR cells represent a multipotent stage in between true MSCs and more mature stromal cell
populations.
Manipulation of CAR differentiation has been shown to affect B lymphopoiesis. Deletion
of the Foxc1 transcription factor in CAR cells, either constitutively or inducibly in adult mice,
results in disturbed hematopoiesis, including deficits in CLP, pro-B, and pre-B cell number.
Constitutive deletion results in adipocyte infiltration of the marrow, but osteoblast number and
cortical thickness remain normal at the time of analysis. Inducible deletion results in a modest
reduction in overall CAR cell number, increased transcription of adipocyte markers, and
decreased expression of B trophic factors CXCL12 and KITL75. Deletion of Pten within CAR
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cells also results in enhanced adipogenic potential at the expense of osteogenic potential,
however the effect on B lymphopoiesis was not examined 71.
1.2.3. Osteoblasts/osteocytes
Osteoblasts have also been implicated in bone marrow B lymphopoiesis. Osteoblasts are
known to secrete several factors important for B cell development, including IL-7, CXCL12,
IGF-1, RANKL, and IL-676–80. Co-culture of osteoblasts with B progenitors has shown that
osteoblasts can support all stages of B cell development in vitro, and co-culture with
uncommitted progenitors has demonstrated that osteoblastic cells can direct multipotent cells to
differentiate into B cells76. In vivo, osteoblast ablation using a thymidine kinase driven by the
Col2.3 promoter has shown that ablation of osteoblasts leads to a rapid loss of B cells at early
stages of B cell development 76,81. Like other ablation models, however, this model is complicated
by the possibility that loss of B cells is not directly due to loss of osteoblasts but secondary to
other changes occurring in the bone marrow following widespread osteoblast apoptosis.
Other evidence pointing to an important role for osteoblasts in B cell development comes
from conditional deletion models targeting osteoblasts. Conditional knockout of the Gs
signaling molecule in osteoblast precursors decreases bone marrow B cell number and increases
bone marrow neutrophil number. Transplant of bone marrow from conditionally deleted mice
into wild type mice rescues the loss of B cells, indicating that the defect is confined to the nontransplantable stromal compartment. Osteoblasts sorted from conditionally deleted mice have
reduced levels of IL-7 mRNA, and administration of exogenous IL-7 to conditionally deleted
mice partially rescues bone marrow B cell number 82.
Osteocytes embedded in bone matrix also play a role in B lymphopoiesis. Osteocytes
have been reported to be an important source of RANK ligand in the bone marrow 80, which is
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required for normal B cell development. Osteocytes also produce sclerostin, which promotes B
cell survival, perhaps via regulation of CXCL12 production83.
While CAR cells are one potential osteoprogenitor cell, perivascular smooth muscle cells
may also be osteoprogenitors. Alpha smooth muscle actin (SMA)-positive cells line arteries
and arterioles throughout the body, including in the bone marrow. SMA-positive cells are
known to proliferate in the bone marrow after ablation of osteoblasts and to colocalize with
Col3.6-GFP, a marker of early osteoblast development. SMA-positive cells isolated from an

SMA-Gfp reporter mouse have the ability to give rise to osteoblastic and adipogenic cells in
vitro, and in vivo can give rise to cells positive for Col2.3-CFP, a marker of mature osteoblasts,
when injected intrafemorally84. Ng2-Cre, a Cre recombinase reported to target an SMApositive periarteriolar cell population with high level CXCL12 and SCF mRNA, has been shown
to mark vascular smooth muscle cells, osteocytes, chondrocytes, and some osteoblasts in the
bone marrow, but not CAR cells71,85. Whether CAR cells and smooth muscle cells represent two
independent paths of osteogenesis or have a lineal relationship is unknown. Lepr-Cre has been
reported to mark CAR cells but not vascular smooth muscle in the bone marrow71, suggesting
that if a lineal relationship exists, SMA cells are progenitors of CAR cells rather than the
converse. Additionally, Osteocalcin-Cre, a Cre recombinase that efficiently targets osteoblasts,
targets some cells in the central marrow86 that may represent an osteoprogenitor pool. It is
unknown what relationship, if any, the Osteocalcin-Cre-targeted cells have to CAR cells.
1.2.4. IL-7-expressing stromal cells
IL-7 has been reported to be expressed by a bone marrow stromal cell distinct from CAR
cells using immunohistochemical staining against IL-763. Because IL-7 is produced in low
quantity in the bone marrow, however, this staining has been difficult to replicate. To provide an
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additional way to detect IL-7 producing cells, several groups have generated transgenic reporter
mice using segments of the IL-7 promoter to drive a fluorescent reporter or Cre recombinase.
Transgenic mice generated by cloning a fragment of the Il7 promoter upstream of a fluorescent
reporter or Cre recombinase inserted randomly into the genome have produced inconsistent
results, with different expression patterns in mice generated by different groups, perhaps due to
the different lengths of the promoter used to drive expression or due to the region of the genome
in which the cassette is inserted87–90. Only one transgenic reporter has been reported to have bone
marrow expression. In that model, Il7 reporter activity was observed in a central marrow stromal
cell that was not further characterized. Notably, no reporter activity was detected in osteoblasts.
Reporter activity was not observed in other tissues known to have IL-7 expression, however,
making it unclear whether the lack of expression in osteoblasts is a technical limitation of the
model or if osteoblasts truly lack IL-7 expression88 . Two knock-in models in which Gfp is
inserted into the endogenous Il7 locus, which should faithfully report IL-7 transcription, have
recently been reported. In one model GFP expression in bone marrow stromal cell populations
was noted91, while in the other expression in the bone marrow was not described92.
1.2.5. Galectin-1 cells
Galectin-1 is a ligand for the pre-BCR, which promotes proliferation and differentiation
of pre-B cells. Staining for Galectin-1 in the bone marrow reveals that it is widely expressed,
found on both hematopoietic cells and stromal cells. Within stromal cells, Galectin-1 is found on
osteoblasts along the endosteum, cuboidal cells in the central marrow, and fibroblastic reticular
cells in the central marrow. Adoptive transfer experiments in which late pre-B cells were labeled
with a fluorescent dye and transplanted into mice treated with hydroxyurea to clear cycling cells
from the marrow show that late pre-B cells preferentially interact with cuboidal Galectin-1-
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expressing stromal cells in the central marrow, while pro-B and early pre-B cells do not,
suggesting that Galectin-1 cells may represent a specific pre-B niche population. Use of a
transgenic Il7-Cre reporter mouse87 suggests that the IL-7-expressing population is distinct from
the Galectin-1-expressing population; however, it is unclear if the Il7-Cre reporter mouse
faithfully identifies IL-7 expression. Galectin-1 cells were negative for CXCL12 by qPCR,
suggesting that they may also be distinct from CAR cells, though Galectin-1 expression on CAR
cells themselves was not analyzed64.
1.2.6. Dendritic cells
In addition to stromal cells, hematopoietic cells in the bone marrow also play a role in B
cell development. Mature naïve B cells in the bone marrow have a perivascular location and are
in close association with dendritic cells. Use of a CD11c-Dtr ablation model to inducibly delete
dendritic cells results in a loss of mature naïve B cells but no other B cell subpopulations. The
loss of mature naïve B cells is specific to the bone marrow, as mature B cell number is normal in
peripheral lymphoid organs. The defect was shown to be due to decreased mature naïve B cell
survival rather than a defect in homing or retention of B cells in the bone marrow 93.
1.3. G-CSF effects on the bone marrow and B cell development
1.3.1. Introduction to G-CSF
Granulocyte Colony Stimulating Factor (G-CSF) was originally identified from
conditioned media as a factor able to induce differentiation of a leukemic cell line and promote
the outgrowth of granulocytic colonies from murine bone marrow cultures94. In humans, serum
levels of G-CSF rise in the acute phase of bacterial infection and decline in the recovery phase,
consistent with a role for G-CSF in the early immune response95. Animal models provide robust
evidence that G-CSF plays a key role in granulocyte development. Mice deficient for G-CSF
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exhibit a peripheral neutropenia and a depletion of granulocytic precursors, demonstrating a
requirement for G-CSF in baseline granulopoiesis. In a Listeria monocytogenes infection model,
Csf3-/- mice fail to increase granulocyte production, demonstrating that G-CSF is required for
emergency granulopoiesis as well96. Similarly, mice deficient for the G-CSF receptor (CSF3R)
are neutropenic, and the neutrophils that are produced have elevated rates of apoptosis97.
Surviving neutrophils are able to generate superoxide and degranulate normally but have
impaired chemotaxis in response to multiple different stimuli due to defective adhesion and
integrin signaling98. The ability of G-CSF to promote granulocyte development is used clinically
to treat patients with deficient neutrophil number99. In addition to its role in granulocyte
development, G-CSF treatment also results in the mobilization of HSPCs from the bone marrow
into the peripheral circulation, where they can be collected and used in hematopoietic stem cell
transplant100.
1.3.2 The role of G-CSF in B lymphopoiesis
G-CSF has also been reported to affect B cell development. While the exact mechanisms
by which G-CSF interacts with B lymphopoiesis are unclear, there are several lines of evidence
that point to a relationship between granulopoiesis, G-CSF, and lymphopoiesis. Adjuvantinduced inflammation results in a temporary increase in bone marrow granulopoiesis at the
expense of lymphopoiesis and mobilizes bone marrow lymphocytes into the periphery. In this
model, developing granulocytes and lymphocytes were observed to occupy similar sites in the
bone marrow, suggesting that competition for resources may lead to a reciprocal
relationship101,102. Implantation of the CE murine tumor line into a wild type mouse induces a
peripheral neutrophilia and depletion of bone marrow lymphocytes. This phenotype is
recapitulated with the injection of conditioned media from CE cells grown in vitro, and a
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candidate approach identified G-CSF as the factor responsible for both peripheral neutrophilia
and medullary lymphopenia103. Transgenic mice overexpressing G-CSF show a reduction in
bone marrow B lymphocytes and CFU-pre-B colonies104, while mice deficient for G-CSF or
CSF3R show the opposite phenotype, with increased B lymphocytes and CFU-pre-B in the bone
marrow96,105.
G-CSF is known to affect multiple stromal cell populations in the bone marrow. G-CSF
treatment induces osteoblast apoptosis106, consistent with reports that transgenic mice
overexpressing G-CSF and human receiving chronic G-CSF treatment develop osteoporosis107–
109

. G-CSF treatment downregulates osteoblastic genes as well as B-trophic factors CXCL12, IL-

7, and KITL mRNA in Nestin-Gfp+ stromal cells68. G-CSF treatment also increases CFU-F
number in the bone marrow and increases the osteogenic commitment of CFU-F cells106,110,
perhaps to compensate for G-CSF-induced osteoblast apoptosis.
The mechanisms by which G-CSF inhibits B lymphopoiesis are largely unknown. G-CSF
is known to work through both direct and indirect mechanisms. CSF3R is expressed on a variety
of hematopoietic cells, and the defect in granulopoiesis in Csf3r knockout mice is primarily due
to a cell intrinsic defect in granulocyte progenitors105. It is unclear if CSF3R is expressed on B
cells, as some groups report CSF3R expression on some populations of bone marrow and
peripheral blood B lymphocytes, while others report expression only on myeloid-lineage
cells111,112. G-CSF is also known to affect other cell populations via an indirect mechanism.
Chimeric mouse models demonstrate that CSF3R expression is required on a cell in the
transplantable compartment, but not HSPCs themselves, in order for G-CSF-induced HSPC
mobilization to occur113. Similarly, G-CSF signaling through an intermediary in the
hematopoietic compartment is sufficient to induce osteoblast apoptosis 106. Evidence from
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multiple groups working independently suggests that G-CSF signaling in cells of the monocytemacrophage lineage is responsible for mediating these effects114–116.
Recent evidence shows that G-CSF results in the mobilization of B cells from the bone
marrow and B cell apoptosis. Transgenic expression of the anti-apoptotic protein BCL2 partially
rescues this phenotype, though this evidence is complicated by the fact that the transgenic line
utilized expresses BCL2 in all hematopoietic cells, not just B cells, making it unclear if B cell
apoptosis is a direct or indirect consequence of G-CSF-treatment. It is currently unknown if the
G-CSF-induced loss of bone marrow B lymphocytes is merely a side effect of increased
granulopoiesis displacing developing B lymphocytes, or if G-CSF actively suppress B
lymphopoiesis by altering the bone marrow microenvironment. G-CSF may signal directly
through B cells to induce apoptosis, decrease proliferation, alter lineage commitment of B
progenitors, or mobilize B cells to peripheral organs, or indirectly alter B lymphopoiesis by
regulating the bone marrow microenvironment in a manner less permissive of B cell
development.
1.4. The role of the niche in B-ALL
The bone marrow microenvironment is known to play an important role in B cell-acute
lymphoblastic leukemia (B-ALL). Despite having high rates of response to induction
chemotherapy, adult B-ALL has a poor overall prognosis, with a 5 year survival rate of
approximately 10% for patients over the age of 60117,118. The poor survival rate is believed to be
due in part to outgrowth of minimal residual disease consisting of chemotherapy-resistant
leukemic cells. Work from several groups has produced evidence that the B cell niche in the
bone marrow may play a role in protecting leukemic blasts from the full effect of chemotherapy,
allowing subpopulations of blasts to acquire additional mutations leading to chemoresistance.
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CXCL12-CXCR4 signaling plays an important role in B-ALL engraftment in the bone marrow,
and the CXCR4 antagonist/partial agonist AMD3100 has been shown to synergize with
chemotherapy in mouse models of ALL119,120. In vitro, co-culture of B-ALL tumor cell lines with
stromal cells results in decreased rates of B-ALL apoptosis, both at baseline and in response to
chemotherapy121. In vivo, B-ALL cell lines engrafted into mice show increased quiescence
within certain bone marrow microenvironments, and neutralization of niche factors synergizes
with chemotherapy to increase survival122. Better understanding how the microenvironment
regulates B cell development, and how G-CSF shapes that regulation, may provide insights that
can be applied to treating human B-ALL.
1.5. Summary
B lymphopoiesis in the bone marrow is regulated by the B cell niche, consisting of stromal
cells, hematopoietic cells, and secreted factors that coordinate B cell proliferation and
differentiation, and disruption of the niche can impair normal B cell production. How different
niche populations regulate developing B cells is largely unknown, however. Administration of
G-CSF also disrupts B lymphopoiesis, but the mechanisms mediating this disruption are unclear.
Better understanding how niche populations support B cell development, and how G-CSF
impairs B cell development, will lead to a better understanding of how bone marrow niches
regulate B lymphopoiesis and how niche regulation may be exploited to treat B cell
malignancies.
In Chapter 2, the mechanisms underlying G-CSF-mediated B cell suppression will be
explored. In Chapter 3, the role of CXCL12 from different stromal cell populations in regulating
B cell development will be dissected. Finally, in Chapter 4, these findings on niche regulation of
B lymphopoiesis will be summarized and future directions will be outlined.
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1.6 Figures

Figure 1.1. Overview of bone marrow B cell development. Shown are the surface markers,
immunoglobulin recombination status, and cytokine responsiveness of different stages of bone
marrow B cells.
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Figure 1.2. Cartoon of different niche models. A. Different niche cells produce factors required
for distinct stages of B lymphopoiesis, and B cells at different developmental stages migrate to
different niche cells. B. A dominant niche cell type is capable of producing factors required for
different stages of B lymphopoiesis, producing specific cytokines appropriate for the
developmental stage of B cells it is in contact with. C. A dominant niche cell type constitutively
produces B trophic factors, while regulation of receptor expression on developing B cells
restricts signaling to the appropriate developmental stage. D. Developing B cells are in contact
with one type of niche cell but also receive trophic support from distant support cells.
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CHAPTER 2: G-CSF REPROGRAMS STROMAL CELLS TO ACTIVELY SUPPRESS B
LYMPHOPOIESIS

2.1. INTRODUCTION
The production of hematopoietic cells in the bone marrow is a tightly regulated process
that is highly responsive to environmental stimuli. In response to acute infectious stress, there is
a shift in hematopoiesis in the bone marrow from lymphopoiesis to granulopoiesis. Granulocytecolony stimulating factor (G-CSF) is often induced during the acute phase of bacterial
infection95, and it has been established as the key regulator of both steady-state and stress
granulopoiesis96,97. G-CSF has also been shown to decrease bone marrow B cell number, but the
mechanisms by which G-CSF targets B cells in the bone marrow are largely unknown.
B lymphopoiesis is dependent on the production of supportive signals by bone marrow
stromal cells. Moreover, there is evidence that different stages of B cell development are
supported by distinct stromal cell populations, suggesting the presence of several lymphoid
niches in the bone marrow. Pre-pro B cells are in direct contact CAR cells, perivascular stromal
cells with osteogenic and adipogenic potential63,71,74. CAR cells produce high level CXCL12 and
KIT ligand72,74, important factors for B cell development, and conditional ablation of CAR cells
or deletion of Cxcl12 from CAR cells results in the loss of early B cell precursors70,71. Deletion
of the transcription factor Foxc1 in CAR cells results in increased adipocytic differentiation,
decreased production of CXCL12 and KIT ligand, and decreased B cell number75, indicating that
alterations in CAR cell differentiation can also modulate hematopoiesis. IL-7-expressing cells
are in contact with pro-B cells63, while Galectin-1 cells have been reported to be in contact with
later pre-B cells64. Osteoblasts and osteocytes are known to produce a number of factors
important for developing B cells, including IGF-1, IL-6, IL-7, RANK ligand, and CXCL1276–80,
24

and ablation of osteoblasts is also known to impair B lymphopoiesis 76,81. G-CSF is known to
induce osteoblast apoptosis106, but its effect on other stromal cells is unclear. Understanding how
G-CSF regulates B-supportive stromal cells in the bone marrow may lead to a better
understanding of how stromal cells and hematopoietic cells regulate one another. Because
malignant cells are believed to co-opt the stromal microenvironment for engraftment and
survival signals, stromal cells may be able to be targeted to treat bone marrow malignancies.

2.2 MATERIALS AND METHODS
Mice. All mice were backcrossed at least 10 generations and maintained on a C57BL/6
background with the exception of Cxcl12gfp mice. Cxcl12gfp mice were a gift from Takashi
Nagasawa (Kyoto University, Japan), and Col2.3-Gfp mice were a gift from David Rowe
(University of Connecticut). E-mu-Bcl2 mice were a gift from Barry Sleckman. The generation
of CD68:Csf3r Csf3r-/- mice has been previously described116. Mice were maintained under
standard pathogen free conditions according to methods approved by the Washington University
Animal Studies Committee. G-CSF was obtained from Amgen.

Blood, bone marrow, spleen, and lymph node analysis. Blood, bone marrow, spleen, and
lymph node cells were harvested using standard techniques and quantified using a Hemavet
automated cell counter (CDC Technologies) or Cellometer (Nexelcom).

Generation of bone marrow chimeras. Bone marrow from Csf3r-/- mice expressing Ly5.2 was
mixed at a 2:1 ratio with wild-type marrow expressing Ly5.1/5.2 and transplanted retro-orbitally
into lethally irradiated Ly5.1 recipients. A total of 3 × 106 cells were injected per recipient
mouse. Recipient mice were conditioned with 1100 cGy from a 137Cesium source at a rate of
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approximately 95 cGy/minute before transplantation. Prophylactic antibiotics (trimethoprimsulfamethoxazole; Alpharma, East Bridgewater, NJ) were given during the initial 2 weeks after
transplantation. Mice were analyzed 8 to 10 weeks after transplantation.

Flow cytometry. Flow cytometry data were collected on a Gallios 10-color, 3-laser flow
cytometer (Beckman Coulter) and analyzed with FlowJo software (Treestar). Cells were stained
by standard protocols with the following antibodies (eBiosciences unless otherwise noted): Ly5.1
(A20, CD45.1), Ly5.2 (104, CD45.2), Ly6C/G (RB6-8C5, Gr-1), CD3e (145-2C11), CD45R
(RA3-6B2, B220), CD11c (N418), TER-119, Flk2 (A2F10), (LG.7F9), IL-7Ra (gift of Deepta
Bhattacharya, Washington University), Ly6D (49-H4, BD Biosciences), CD11c (N418), NK1.1
(PK136), IgM (II/4), IgD (11-26c), PE-Cy7-conjugated CD19 (eBio1D3), CD43 (S7, BD
Biosciences), CD45 (30-F11), CD31 (390), and CD11b (M1/70).
For cell cycle analysis, cells were fixed using the Cytofix/Cytoperm kit (BD
Biosciences). After fixation, cells were stained with Ki-67 (B56, BD Biosciences) and
resuspended in 1 mg/mL of 4',6-diamidino-2-phenylindole (DAPI) in PermWash buffer.
Doublets were excluded by FSC vs. FSC-W gating. Fractions A-D were combined into one
group as B220+ CD3e- CD11c- NK1.1- IgM- IgD- or B220+ IgM- IgD-.
For apoptosis analysis, macrophages were depleted by incubating flushed bone marrow
cells in sterile cell culture dishes for 1 hour. Non-adherent cells were transferred to new dishes
for an additional 3 hours. Cells were washed and stained for surface markers using standard
protocols, then stained for Annexin V (BD Biosciences, eBioscience) and resuspended in 1
mg/ml DAPI.
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Stromal cell analysis and sorting. To extract bone marrow stromal cells, femurs and tibias
were crushed with a mortar and pestle in phosphate buffered saline (PBS). Cells in suspension
were collected and stored on ice while bone chips and aggregates were digested using
collagenase type II (3mg/mL, Worthington Biochemical) and dispase (4mg/mL, Roche) at 37°C
for 1 hour in a shaking water bath. Following digestion both fractions were pooled, red blood
cells lysed, and analyzed. Cells were stained with 7-amino-actinomycin D (7AAD) to exclude
dead cells and autofluorescent debris. CAR cells were defined as CD45 - TER119- CD31GFPbright cells in mice carrying the Cxcl12gfp transgene. Osteoblasts were defined as CD45 TER119- CD31- GFP+ cells in mice carrying the Col2.3-Gfp transgene. Cell sorting was
performed on Reflection (iCyt) or Synergy (Sony) cytometers.

Immunostaining of bone sections. Femurs and tibias were harvested and fixed for 16-24 hours
in 4% paraformaldehyde (Sigma-Aldrich) at 4oC. Bones were washed twice in PBS, decalcified
in 14% ethylenediaminetetraacetic acid (EDTA) pH 7.4 solution for 3-5 days, and cryoprotected
in 30% sucrose in PBS for 16-24 hours. Bones were then snap frozen in OCT media (TissueTek), and tissue blocks were sectioned (10 µm or 100 µm) using the CryoJane (Leica
Biosystems). Antibodies used included anti-mouse CD45R (RA3-6B2, B220) and anti-mouse
IgM (II/4). Sections were washed in TNT buffer (0.1 M Tris-HCl, 0.15 M NaCl, 0.05% Tween20) and mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen). Slides were
imaged using a LSM 700 confocal microscope and ZEN imaging software (Zeiss). Volocity
image processing software (Perkin Elmer) was used to calculate distances between cells.
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Quantitative RT-PCR. For total bone marrow RNA, femurs or tibias were flushed with 1 mL of
Trizol (Invitrogen) and RNA was prepared according to manufacturer’s instructions. cDNA was
prepared using SuperScript III (Invitrogen) or Taqman RT Enzyme (Applied Biosystems). qRTPCR was performed using the TaqMan Universal RT Master Mix (Applied Biosystems) using no
template and no RT controls. Data was collected on a 7300 Real-Time PCR System (Applied
Biosystems). Primers were: CXCL12 forward, 5’-GAGCCAACGTCAAGCATCTG-3’;
CXCL12 reverse, 5’-CGGGTCAATGCACACTTGTC-3’; CXCL12 dT-FAM/TAMRA probe,
5’-TCCAAACTGTGCCCTTCAGATTGTTGC-3’; β-actin forward, 5’ACCAACTGGGACGATATGGAGAAGA-3’; β-actin primer; β-actin dT-VIC/TAMRA probe,
5′-AGCCATGTACGTAGCCATCCAGGCTG-3′. IL-6, KIT ligand, FLT3L, BAFF, IGF-1, and
RANKL primers and probes were purchased from Applied Biosystems. IL-7 qPCR was
performed using SYBR Green and the following primers: IL-7 forward, 5′TCTGCTGCCTGTCACATCATC; IL-7 reverse, 5′GGACATTGAATTCTTCACTGATATTCA, or primers from Applied Biosystems.

RNA expression profiling. Lineage- CD45- GFPbright CAR cells from Cxcl12gfp mice or lineageCD45- GFP+ osteoblasts from Col2.3-Gfp mice were sorted directly into lysis buffer, and RNA
was prepared using the RNA XS column kit (Macherey-Nagel, Bethlehem, PA) according to the
manufacturer’s directions. RNA was amplified using the NuGen Ovation system (NuGen, San
Carlos, CA), and hybridized to the Affymetrix MoGene 1.0 ST array. Data normalization was
performed using the Robust Multichip Average (RMA) algorithm. Submission of this RNA
expression data to Gene Expression Omnibus is in progress.
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CFU-F assay. Bone marrow cells were harvest by standard techniques. For CFU-F, cells were
plated in MEM with 10% lot-tested fetal calf serum. Cells were left undisturbed for 1 week,
then media was subsequently changed every 3-4 days. Alkaline phosphatase staining was
performed at 2 weeks using the Leukocyte Alkaline Phosphatase Kit (Sigma Aldrich). For
osteoblastic culture conditions, CFU-F medium was supplemented with 10 mM gylcerophosphate (Sigma Aldrich) and 50 ug/ml ascorbic acid. Cells were left undisturbed for 1
week, and media was subsequently changed every 3-4 days. Von Kossa staining was performed
after 3 weeks of culture using 2.5% silver nitrate (Sigma Aldrich).

Statistics. Significance was determined using Prism software (GraphPad). Unless otherwise
stated, statistical significance of differences was calculated for two groups using Students t-test
and 3 or more groups using 1- or 2-way ANOVA. P-values less than 0.05 were considered
significant. All data are presented as mean ± SEM. The RNA expression profiling data was
analyzed using Statistical Analysis of Microarrays (SAM). A FDR < 0.05 was considered
significant.

2.3. RESULTS
2.3.1. G-CSF suppresses bone marrow B lymphopoiesis at all stages of bone marrow B cell
development
To examine the effect of G-CSF on bone marrow B lymphopoiesis, wild-type mice were
treated with G-CSF for 5 days and lymphocyte number quantified by flow cytometry. Consistent
with previous reports103,123, total B cell number was markedly reduced (8.1 ± 0.9-fold) compared
with control mice (Figure 2.1B), while neutrophil number, as expected, was significantly
increased (Figure 2.1A). Likewise, G-CSF treatment was associated with significant reductions
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in T cells, natural killer cells, and CD11c+ dendritic cells in the bone marrow (Figure 2.1C).
Interestingly, the loss of B cells in the bone marrow was delayed, becoming significant after 3
days of G-CSF, reaching a nadir after 7 days of G-CSF, and returning to near normal levels 7
days after stopping G-CSF (Figure 2.1D). Bone marrow B lymphopoiesis proceeds through a
well-described sequence of steps, beginning with a common lymphoid progenitor (CLP) with B,
T, NK, and dendritic cell potential to mature naïve recirculating B cells. To determine which
stages of B cell development are affected by G-CSF treatment, we measured these cell
populations in the bone marrow via flow cytometry (Figure 2.2A & 2.2B). Surprisingly,
although all lymphoid lineages were suppressed, no decrease in CLP number was observed after
G-CSF treatment. Instead, G-CSF treatment resulted in a progressive loss of B cells at discrete
stages of development. A modest loss of BLP and pre-pro-B cells suggests an early defect in B
lymphopoiesis. A further decrease in B cells was observed in the transition from pre-pro-B to
pro-B cells. Finally, a severe reduction in mature naïve B cells was observed, suggesting a
further defect in B lymphopoiesis between immature B and mature B cells (Figure 2.2C). These
data show that G-CSF treatment disrupts bone marrow B lymphopoiesis at multiple discrete
stages of development.

2.3.2. G-CSF treatment is associated with increased cycling and apoptosis of certain B cell
subsets in the bone marrow
We next examined the effect of G-CSF on B cell proliferation and apoptosis. We
focused our analysis on days 3-4 of G-CSF, the time at which B cell number in the bone marrow
most rapidly decreases. In control mice, there was a progressive increase in quiescence from
early B cell precursors (Fraction A-D) to mature B cells (Fraction F) (Figure 2.3A and 2.3B). G-
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CSF treatment was associated with a significant increase in cycling cells at all measured stages
of B cell development, and was most striking in Fraction A-E cells. Thus, the loss of B cells in
the bone marrow is not caused by decreased B cell proliferation. Apoptosis was assessed in B
cells by measuring cell surface expression of Annexin V (Figure 2.3.C). In the bone marrow, we
detected a significant increase in apoptosis in mature naïve B cells but not in early B precursors
or immature B cells (Figure 2.3D).

2.3.3. G-CSF treatment is associated with peripheral apoptosis of developing B cells
G-CSF is known to be a potent mobilizer of neutrophils and hematopoietic stem cells
from the bone marrow. However, no significant increase in total B cell number in the peripheral
blood, spleen, or lymph nodes was observed after G-CSF treatment (Figure 2.4A). Thus, the loss
of B cells in the bone marrow induced by G-CSF is not secondary to their bulk mobilization into
the peripheral circulation. We next examined B cell subpopulations in the spleen following GCSF treatment. While overall B cell number and mature B cell number in the spleen were not
increased, a significant increase in certain precursor B cell populations was observed after GCSF treatment (Figure 2.4B). To determine if B cell precursors mobilized to the spleen undergo
elevated rates of apoptosis, we performed Annexin V staining. Regardless of G-CSF treatment,
compared with the bone marrow, a much higher percentage of Fraction A-D cells in the spleen
were apoptotic (Figure 2.4C), indicating that the spleen does not provide a supportive
environment for early B cell development. Consistent with this hypothesis, mice carrying the Emu-Bcl2 transgene, expressing anti-apoptotic BCL2 in B cells, show an accumulation of early B
precursors in the spleen after G-CSF treatment (Figure 2.4D) similar to a recent report using
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Vav-Bcl2123. These data suggest that early B cell precursors mobilized to the spleen are destined
for rapid clearance.

2.3.4. Mature naïve B cells do not home to the bone marrow of G-CSF-treated recipients
Despite seeing elevated Annexin V staining on mature B cells in the bone marrow of GCSF-treated mice, we did not observe a significant rescue of mature B cell number in the bone
marrow of E-mu-Bcl2 mice treated with G-CSF (Figure 2.5A). Because mature naïve B cells
home to the bone marrow following peripheral maturation, it is possible that surviving mature
naïve B cells do not home or are not retained in the bone marrow of G-CSF-treated mice. To test
this hypothesis we performed an adoptive transfer experiment in which splenocytes from a CAGGFP mouse, ubiquitously expressing GFP, were adoptively transferred into PBS or G-CSFtreated recipients. 24 hours after transfer recipients were sacrificed and the number of GFP+ IgD+
cells in the bone marrow was quantified by flow cytometry (Figure 2.5B). We found a significant
reduction in the number of GFP+ IgD+ cells in the bone marrow, suggesting that mature naïve B
cells fail to home or be retained in the bone marrow of G-CSF-treated mice (Figure 2.5C). These
results indicate that increased survival alone may not be sufficient to rescue mature B cell
number in the bone marrow. Consistent with this hypothesis, we observed increased mature B
cell number in the spleen of E-mu-Bcl2 mice treated with G-CSF (Figure 2.5D).

2.3.5. G-CSF signals through monocyte-macrophage lineage cells to downregulate B
trophic factors in the bone marrow
The G-CSF receptor (CSF3R) is expressed on a subset of multipotent progenitors and B
cells111,124. Thus, it is possible that G-CSF acts in a cell intrinsic fashion to suppress B
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lymphopoiesis. Alternatively, G-CSF treatment also alters the bone marrow
microenvironment 79,106,113, raising the possibility of a non-cell autonomous mechanism. To
address this question, we generated Csf3r-/- (G-CSF-receptor deficient) mixed bone marrow
chimeras by transplanting a mixture of wild-type and Csf3r-/- bone marrow cells into lethally
irradiated wild-type recipients. After engraftment, mice were either left untreated or treated with
G-CSF for 5 days (Figure 2.6A). Following G-CSF treatment, wild-type B cells in the bone
marrow were reduced 10-fold compared to untreated mice. Importantly, a similar decrease in
Csf3r-/- B cells was observed (12-fold decrease compared with untreated mice, Figure 2.6B). In
contrast, G-CSF is known to act in a cell intrinsic fashion to stimulate granulopoiesis 105.
Accordingly, G-CSF treatment of the mixed chimeras resulted in an expansion of only Csf3r+/+
neutrophils (Figure 2.6C). Together, these data show that G-CSF acts in a non-cell intrinsic
fashion to suppress B lymphopoiesis.
Since G-CSF acts non-cell intrinsically to suppress bone marrow B cell development, we
examined the bone marrow microenvironment for potential candidates mediating G-CSFinduced B cell suppression. Bone marrow stromal cells are known to produce a number of
trophic factors important for B cell development, including CXCL12, IL-7, interleukin-6 (IL-6),
FLT3 ligand, KIT ligand, insulin-like growth factor 1 (IGF-1), RANK ligand (RANKL), and B
cell activating factor (BAFF). We measured the mRNA expression of these genes in the bone
marrow by flushing femurs with Trizol. While RANKL mRNA expression was not significantly
altered, significant decreases in CXCL12 (5.8-fold), IL-6 (4.3-fold), IL-7 (7.4-fold), KITL (5.5fold), FLT3L (2.2-fold), IGF-1 (7.9-fold), and BAFF (9.7-fold) mRNA in the bone marrow were
observed with G-CSF treatment (Figure 2.6D).
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G-CSF works through cells of the monocyte-macrophage lineage to mobilize
hematopoietic stem and progenitor cells from the bone marrow 114–116. To determine if monocytemacrophage lineage cells were also responsible for mediating G-CSF-induced B cell
suppression, we used CD68:Csf3r Csf3r-/- transgenic mice in which the G-CSF receptor is
expressed only on monocyte-macrophage lineage cells116. After 5 days of G-CSF treatment, bone
marrow B cell number was significantly decreased relative to PBS-treated mice (Figure 2.7A).
As in wild type mice treated with G-CSF, we also observed mobilization of B precursors to the
spleen (Figure 2.7B) and downregulation of B trophic factors in the bone marrow (Figure 2.7C)
in CD68:Csf3r Csf3r-/- mice. Collectively, these data show that G-CSF signaling in monocytemacrophage cells results in the downregulation of B trophic factors in the bone marrow
microenvironment, promoting B cell mobilization and apoptosis.

2.3.6. G-CSF reprograms CAR cells towards an osteoblastic fate
CAR cells are mesenchymal progenitors that represent an important component of the
bone marrow lymphoid niche63,74, and alterations in CAR cell potential have been reported to
affect the ability of CAR cells to support B lymphopoiesis75. To determine if G-CSF targets CAR
cells, we used transgenic mice carrying a knock-in of the green fluorescent protein gene (Gfp)
into the Cxcl12 locus that identifies CXCL12 expressing cells, including GFP hi CAR cells63.
Surprisingly, CAR cell number increased after G-CSF treatment (Figure 2.8A), but we detected
no change in CAR cell morphology or reticular processes (Figure 2.8B). CAR cells are
mesenchymal progenitors with adipogenic-osteogenic lineage potential. RNA expression
profiling of sorted CAR cells showed that G-CSF treatment significantly suppressed genes
associated with adipocyte differentiation, including PPAR, lipoprotein lipase, and adiponectin,
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but not osteoblast differentiation (Figure 2.8C & 2.8D, Table 2.1). Gene set enrichment analysis
indicated a relative loss of adipogenesis in G-CSF-treated CAR cells (Figure 2.8E). To assess
lineage commitment of CAR cells, colony-forming unit-fibroblast (CFU-F) assays were
performed. CAR cells are the major source of CFU-F in the bone marrow71, and consistent with
an increase in CAR cell number (Figure 2.8A), G-CSF treatment results in an increase in CFU-F
(Figure 2.9A). Osteogenic potential was assessed by alkaline phosphatase staining of CFU-F.
Whereas, alkaline-phosphatase positive CFU-F were significantly increased with G-CSF
treatment, no change in alkaline phosphatase-negative CFU-F were observed (Figure 2.9B).
Consistent with this finding, culture of CFU-F under osteogenic conditions showed a 4.74 ±
2.98-fold increase in CFU-OB (Figure 2.9C). Collectively, these data suggest that G-CSF
treatment support the osteogenic potential of CAR cells, while suppressing adipogenic potential.

2.3.7. G-CSF suppresses CAR cell expression of B trophic factors
CAR cells produce many of the B trophic factors suppressed by G-CSF. RNA expression
profiling of sorted CAR cells after G-CSF treatment revealed that CAR cells constitutively
express CXCL12, IL-7, Kit ligand, IGF-1, and FLT3 ligand, and expression of all of these genes,
except FLT3 ligand, was decreased following G-CSF treatment (Figure 2.10A & 2.10B, Table
2.1). CAR cells also express Galectin-1, associated with a stromal B niche population64, though
expression is not significantly altered with G-CSF treatment. Similarly, we observe a nonsignificant reduction in the expression of FOXC1, a transcription factor whose expression is
correlated with CAR support of B lymphopoiesis75. Consistent with prior reports, we show that B
cell precursors in the bone marrow localize near CAR cells (Figure 2.10C). After G-CSF
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treatment, although the number of B cell precursors is markedly reduced, the remaining cells
remain in close proximity to CAR cells (Figure 2.10D).

2.3.7. G-CSF suppresses osteoblasts and osteoblast expression of B trophic factors
Osteoblasts also are an important component of the bone marrow lymphoid niche 76,81,82.
As reported previously, G-CSF treatment results in a loss of mature osteoblasts in the bone
marrow106, as assessed by flow cytometry for Col2.3-GFP+ stromal cells (Figure 2.11A). We
next sorted osteoblast lineage cells using the Col2.3-GFP transgenic mice. Similar to CAR cells,
G-CSF resulted in a marked suppression of several key B trophic factors, including CXCL12, IL7, and KIT ligand (Figure 2.11B).

2.4. DISCUSSION
G-CSF has previously been reported to be the major cytokine regulating the shift from bone
marrow lymphopoiesis to granulopoiesis in response to infectious stress 96,97,103,105. In the present
study, we show that G-CSF-induced B cell suppression is not a passive process due to myeloid
expansion or peripheral mobilization of lymphocytes, but instead an active process mediated by
alterations in the bone marrow microenvironment. Despite the dramatic loss of B cells, T cells,
NK cells, and dendritic cells, phenotypic CLP number in the bone marrow is normal, suggesting
that G-CSF does not affect commitment of hematopoietic stem cells to the lymphoid lineage.
Our data show that G-CSF suppresses B lymphopoiesis at multiple discrete stages of
development, including: 1) production and/or maintenance of BLP; 2) the transition of pre-pro-B
cells to pro-B cells; and 3) maintenance of mature B cells in the bone marrow. Our data suggest
that the loss of mature B cells in the bone marrow is due, at least in part, to increased apoptosis,
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consistent with a previous report indicating that loss of dendritic cells leads to decreased mature
B survival93. Our data also indicate that G-CSF results in impaired homing or retention of
mature B cells in the bone marrow, suggesting that defective B cell trafficking may contribute to
the loss of mature B cells. The decrease in B cell precursors is due, again at least in part, to their
mobilization to the spleen where they undergo high rates of apoptosis. Indeed, a previous study
showed that the spleen does not provide a supportive microenvironment for early stages of B cell
development20. Our data are broadly consistent with a study by Winkler et al, which showed that
enforced expression of BCL2 partially rescued the G-CSF-induced loss of bone marrow B
cells123. While both studies noted a loss of bone marrow B cells at early stages of development,
in contrast to that study we did not observe a rescue of pre-pro-B cells in the bone marrow. We
also observed an accumulation of early B precursors in the spleen of E-mu-Bcl2 mice treated
with G-CSF relative to PBS-treated E-mu-Bcl2 mice or wild type G-CSF-treated mice, while in
their study Vav-Bcl2 mice had similarly elevated numbers of B precursors in the spleen whether
treated with PBS or G-CSF. These discrepancies may be due to the different Bcl2 transgenes
used, since E-mu-Bcl2 is restricted to B lineage cells while Vav-Bcl2 is expressed in all
hematopoietic cells, suggesting that G-CSF-induced apoptosis of other hematopoietic cell types
may play a role the impairment of B lymphopoiesis by G-CSF.
Surprisingly, we observed that G-CSF treatment is associated with increased proliferation of
B cell precursors. Proliferation of developing B cells in the bone marrow is tightly regulated to
allow for rearrangement of immunoglobulin chains in non-dividing cells, since rearrangement
within dividing cells can lead to genetic instability, cell death, or leukemic
transformation39,41,42,125,126. Of note, IL-7 negatively regulates immunoglobulin rearrangement
by suppressing expression of recombination activating gene-1 (RAG1)40,43,44. Thus, G-CSF-
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induced suppression of IL-7 expression in the bone marrow may promote immunoglobulin gene
rearrangement in proliferating B cells, leading to increased cell death.
Stromal cells are physically associated with hematopoietic stem cells, lymphoid and
myeloid progenitors, and lineage committed hematopoietic populations in the bone marrow
where they provide supportive and regulatory signals in specialized niches 63,64,68,70,72–75,93,127–130.
Under steady state conditions, niche signals support a balance of lymphopoiesis and
myelopoiesis. We show that G-CSF specifically targets stromal cells in lymphoid niches to
actively suppress lymphopoiesis. Of note, G-CSF does not directly target stromal cells; instead,
it directly targets monocytic cells in the bone marrow that, in turn, regulate stromal cell function.
G-CSF has been reported to utilize a similar mechanism to induce hematopoietic stem and
progenitor cell mobilization by our and other groups114–116.
G-CSF works in part by targeting CAR cells, a multipotent stromal cell population that
gives rise to bone marrow adipocytes and osteoblasts71,74. CAR cells are known to be in contact
with pre-pro-B cells63, and ablation of CAR cells results in apoptosis of pro-B cells74. Recent
work from two independent groups has focused on manipulation of CAR cell differentiation.
Deletion of Pten in CAR cells results in enhanced adipocyte potential and downregulation of the
osteogenic transcription factor Runx271. Likewise, deletion of the Foxc1 transcription factor in
CAR cells results in enhanced expression of adipogenic genes, increased adipogenesis, decreased
transcription of CXCL12 and KIT ligand, and decreased ability to support B lymphopoiesis75. To
our knowledge, ours is the first study to report the ability of an exogenous factor, G-CSF, to
influence CAR cell differentiation in vivo. Our findings that G-CSF increases CAR cell number
and osteogenic potential are consistent with previous reports that CAR cells contain most of the
CFU-F activity in the bone marrow71 and that G-CSF increases CFU-F number in the bone
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marrow106,110. G-CSF treatment results in decreased CAR cell expression of important B trophic
factors including CXCL12, IL-7, IGF-1, and KIT ligand. Interestingly, while Foxc1 deletion is
associated with increased adipogenesis, decreased CXCL12, decreased KIT ligand, and
decreased ability to support B lymphopoiesis75, G-CSF treatment impairs B lymphopoiesis while
decreasing adipogenic potential in CAR cells, suggesting that osteogenic potential in CAR cells
does not serve as a surrogate for B niche function. As reported previously, G-CSF treatment
results in a modest decrease in mature osteoblasts106, which have been implicated in B cell
homeostasis76,81,82. It also suppresses osteoblast production of B trophic factors, including
CXCL12, IL-7, and KIT ligand. Of note, a previous study showed that G-CSF also targets
Nestin-GFP+ stromal cells, altering their expression of certain HSC maintenance genes 68. Thus,
G-CSF treatment appears to broadly affect stromal cells comprising lymphoid and stem cell
niches. Since it is often induced in response to infectious stress, G-CSF provides a mechanism to
broadly shape hematopoiesis through regulation of the bone marrow microenvironment.
Collectively, these data show that G-CSF actively suppresses lymphopoiesis by targeting
stromal cells that contribute to lymphoid niches in the bone marrow. G-CSF reprograms CAR
cells, increasing osteogenic potential, and dramatically inhibits the expression of a number of B
trophic factors in CAR cells and osteoblasts, resulting in impaired B lymphopoiesis at multiple
stages of B cell development. These data raise the possibility that G-CSF treatment, by
disrupting supportive lymphoid niche signals, may render malignant lymphoid cells more
sensitive to chemotherapy. A clinical trial in patients with relapsed or refractory acute
lymphoblastic leukemia is underway to test this hypothesis (clinicaltrials.gov NCT01331590).
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2.7 FIGURES

Figure 2.1. G-CSF treatment suppresses bone marrow B lymphopoiesis. A-C. Wild type
C57BL/6 mice were treated for 5 days with 250 ug/kg G-CSF. Show is the number of bone
marrow neutrophils (A), B220+ B cells (B), T cells, NK cells, or dendritic cells (C). D. Mice
were treated with G-CSF for the number of days indicated and the number of B cells in the bone
marrow was quantified. Data represent the mean ± SEM of 3-12 mice. *P < 0.05; **P < 0.01;
***P < 0.001; ns: non-significant.

41

Figure 2.2. G-CSF treatment suppresses all stages of bone marrow B cell development. A & B.
Shown is the gating strategy used for CLP and BLP (A) or pre-pro-B, pro-B, pre-B, immature B,
and mature naïve B (B). C. Mice were treated with 250 ug/kg G-CSF for 5 days and the number
of B cell subpopulations was enumerated by flow cytometry. Data represent the mean ± SEM of
10-12 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.3. G-CSF treatment is associated with increased cycling and apoptosis in the bone
marrow. A. Representative flow plots showing the gating scheme used for cell cycle analysis. B.
The percentage of cells in the indicated phase of the cell cycle is shown. C. Representative flow
plots showing the gating scheme used for Annexin V staining. D. The percentage of Annexin V+
cells in the indicated B cell subset in the bone marrow is shown. Data represent the mean ± SEM
of 3-9 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.4. G-CSF treatment is associated with B cell progenitor mobilization and apoptosis.
A. Shown is the number of B220+ B cells in spleen (left), peripheral blood (center), or lymph
nodes (right) in PBS or G-CSF-treated mice. B. The number of the indicated B cell subset in the
spleen on day 5 of G-CSF or saline treatment is shown. C. The percentage of Annexin V+ cells in
Fractions A-D cells in the spleen and bone marrow is shown. D. The number of B precursors in
the spleen of wild type or E-mu Bcl2 mice treated with PBS or G-CSF. Data represent the mean
± SEM of 5-14 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.5. Mature B cells fail to home to the bone marrow of G-CSF-treated recipients. A.
The number of mature B cells in the bone marrow of wild type or E-mu Bcl2 mice treated with
G-CSF or PBS. B. CAG-GFP splenocytes were injected into the peripheral blood of PBS or GCSF treated mice. 24 hours after injection bone marrow was harvested. C. The number of GFP+
IgD+ mature B cells in the bone marrow (left panel) or spleen (right panel) 24 hours after
transfer. D. The number of mature B cells in the spleen of wild type or E-mu-Bcl2 mice treated
with G-CSF. Data represent the mean ± SEM of 5-14 mice. *P < 0.05; **P < 0.01; ***P < 0.001;
ns: non-significant.
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Figure 2.6. G-CSF acts in a non-cell autonomous fashion to suppress B lymphopoiesis. A.
Mixed chimera mice were generating by transplanting wild-type (Ly5.1/5.2) and Csf3r-/- (Ly5.2)
bone marrow cells into irradiated wild-type (Ly5.1) recipients at a 1:2 ratio. Eight weeks after
transplantation mice were treated with G-CSF for five days or left untreated, and B cell number
was analyzed by flow cytometry. B & C. Shown is the number of wild-type (Ly5.1+/Ly5.2+) or
Csf3r-/- (Ly5.2+) B cells (B) or neutrophils (C) in the bone marrow of G-CSF treated or untreated
mice. D. Wild-type mice were treated with G-CSF or saline (PBS) for five days, and femurs
directly flushed with Trizol to collect total bone marrow RNA. Shown is the mRNA expression
of the indicated gene relative to -actin mRNA. Data represent the mean ± SEM of 4-5 mice.
*P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.7. G-CSF works through cells of the monocyte-macrophage lineage to suppress B
lymphopoiesis. A. CD68:Csf3r Csf3r-/- mice were treated for 5 days with PBS or G-CSF. Shown
is the number of B cells in the bone marrow for each B cell subset. B. Shown is early B cell
precursors in the spleen of CD68:Csf3r Csf3r-/- mice treated with PBS or G-CSF. C.
CD68:Csf3r Csf3r-/- femurs were flushed with Trizol to collect total bone marrow RNA. Shown
is the mRNA expression of the indicated gene relative to -actin mRNA. Data represent the
mean ± SEM of 7-8 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.8. G-CSF reprograms B cell-supportive CAR cells. A. Cxcl12gfp mice were treated for
7 days with G-CSF or PBS. A. The number of GFPhi CAR cells was quantified by flow
cytometry. B. Representative photomicrographs for PBS-treated (left panel) or G-CSF-treated
(right panel) mice are shown. CAR cells express high levels of GFP (green). Scale bar: 100 µm.
C. Probe signals from RNA expression profiling of sorted CAR cells are shown for the indicated
adipogenic genes. D. Probe signals from RNA expression profiling of sorted CAR cells are
shown for the indicated osteogenic genes. E. Gene Set Enrichment Analysis enrichment plots of
adipogenic gene sets. Data represent the mean ± SEM of 4-11 mice. *P < 0.05; **P < 0.01;
***P < 0.001; ns: non-significant; +FDR < 0.05; +++FDR < 0.001.
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Figure 2.9. G-CSF treatment increases bone marrow osteoblastic potential. Wild type mice
were treated for 7 days with PBS or G-CSF and bone marrow was plated into CFU-F culture. A.
Total CFU-F activity at two weeks. B. The number of CFU-F cultures staining positive or
negative for Alkaline Phosphatase is shown. C. The number of Von Kossa+ CFU-OB colonies at
3 weeks. Data represent the mean ± SEM of 7 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns:
non-significant.
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Figure 2.10. G-CSF targets expression of B trophic factors in CAR cells and osteoblasts. A.
The expression of CXCL12 mRNA relative to -actin mRNA in sorted CAR cells was
determined B. Probe signals from RNA expression profiling of sorted CAR cells are shown for
the indicated B cell trophic genes. C. Representative photomicrographs showing the relationship
of CAR cells to B220+ (cyan) IgM- (red) B cell precursors. D. Quantification of the number of
B220+ IgM- cells within 1 um of a CAR cell. Data represent the mean ± SEM of 3-5 mice. *P <
0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 2.11. G-CSF suppresses osteoblast expression of B trophic factors. A. Col2.3-Gfp mice
were treated for 7 days with G-CSF or PBS. The number of GFP+ osteoblasts was enumerated by
flow cytometry. B. The expression of the indicated genes relative to -actin in mRNA from
sorted osteoblasts is shown. Data represent the mean ± SEM of 7 mice. *P < 0.05; **P < 0.01;
***P < 0.001; ns: non-significant.

51

2.8. TABLES
Gene symbol
PBS
G-CSF
CXCL12
5248 ± 198.8
4081 ± 87.73
KITL
1826 ± 141.5
1087 ± 30.64
IL7
258 ± 20.46
61.14 ± 4.124
FLT3L
221.6 ± 28.32
164.1 ± 8.008
481.1
±
46.10
182.1 ± 9.967
PPAR
Lipoprotein Lipase
3861 ± 87,75
1260 ± 35.85
Adiponectin
2286 ± 217.8
699.5 ± 22.80
Runx2
156.0 ± 18.45
142.0 ± 17.82
Osterix
146.0 ± 9.599
106.5 ± 9.193
Osteopontin
1439 ± 249.4
2852 ± 556.9
Galectin-1
331.4 ± 95.51
594.9 ± 94.15
FOXC1
749.5 ± 74.61
429.1 ± 78.48
Table 2.1. CAR genechip expression profile. CAR cells were defined as GFPhigh CD45- Ter119CD31- cells from Cxcl12-Gfp bone marrow (n=4-5, mean ± SEM is shown).
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CHAPTER 3: CXCL12 FROM BONE MARROW STROMAL CELLS REGULATES B
CELL DEVELOPMENT IN A STAGE-SPECFIC MANNER

3.1. INTRODUCTION
CXCL12, through interaction with its major receptor CXCR4, plays an essential role in B
cell development. Mice deficient for CXCL12 show an early defect in B lymphopoiesis and loss
of developing B cells in the bone marrow13. The CXCL12-CXCR4 signaling axis also plays a
role in human B cell diseases. CXCL12 signaling is important in engraftment and
chemoresistance in B-ALL, while activating mutations in CXCR4 promote lymphoplasmacytic
lymphoma proliferation, dissemination, and chemoresistance31,119–122. In the bone marrow,
CXCL12 is constitutively expressed by several bone marrow stromal cell populations, including
mesenchymal stem/progenitor cells, CAR cells, mature osteoblasts, and endothelial
cells63,66,70,73,74,79,131. While bone marrow-derived CXCL12 is known to be important for B
lymphopoiesis, it is not clear how CXCL12 derived from different stromal cell populations
regulates B cell development. Dissecting how stromal-derived CXCL12 contributes to B
lymphopoiesis will lead to a better understanding of how the stromal microenvironment regulates
hematopoiesis and may provide insight into the complex relationships between different stromal
cell populations. Since CXCL12-CXCR4 signaling is known to play a role in the maintenance of
B cell malignancies, understanding which bone marrow stromal cells provide CXCL12 critical
for specific stages of B lymphopoiesis could provide therapeutically useful insights.

3.2. MATERIALS AND METHODS
Mice. All mice were backcrossed at least 10 generations and maintained on a C57BL/6
background with the exception of Cxcl12-Gfp and Dmp1-Cre mice. Generation of Cxcl12flox
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mice has been previously described70. Prx1-Cre132, Osx-Cre133, Tie-2-Cre134, CAG-GFP, and Ai9
reporter mice were obtained from The Jackson Laboratory. OC-Cre mice were a gift from
Thomas Clemens (Johns Hopkins University, Maryland), Cxcl12-Gfp mice were a gift from
Takashi Nagasawa (Kyoto University, Japan), Cxcr4flox mice were a gift from Robin Klein
(Washington University in St. Louis), and Dmp1-Cre mice were a gift from Roberto Civatelli
(Washington University in St. Louis). Cxcl12+/- mice were obtained through the RIKEN
BioResource Center (Ibaraki, Japan). Mice were maintained under standard pathogen free
conditions according to methods approved by the Washington University Animal Studies
Committee.

Bone marrow and spleen analysis. Bone marrow and spleen cells were harvested using
standard techniques and quantified using a Hemavet automated cell counter (CDC Technologies)
or Cellometer automated cell counter (Nexelcom).

Quantitative RT-PCR. For total bone marrow RNA, femurs or tibias were flushed with 1 mL of
Trizol (Invitrogen) and RNA was prepared according to manufacturer’s instructions. cDNA was
prepared using SuperScript III (Invitrogen) or Taqman RT Enzyme (Applied Biosystems). qRTPCR was performed using the TaqMan Universal RT Master Mix (Applied Biosystems) using no
template and no RT controls. Data was collected on a 7300 Real-Time PCR System (Applied
Biosystems). Primers were: CXCL12 forward, 5’-GAGCCAACGTCAAGCATCTG-3’;
CXCL12 reverse, 5’-CGGGTCAATGCACACTTGTC-3’; CXCL12 dT-FAM/TAMRA probe,
5’-TCCAAACTGTGCCCTTCAGATTGTTGC-3’; β-actin forward, 5’-
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ACCAACTGGGACGATATGGAGAAGA-3’; β-actin primer; β-actin dT-VIC/TAMRA probe,
5′-AGCCATGTACGTAGCCATCCAGGCTG-3′.

Flow cytometry. Flow cytometry data were collected on Gallios 10-color, 3-laser or 4-laser flow
cytometers (Beckman Coulter) and analyzed with FlowJo software (Treestar). Cells were stained
by standard protocols with the following antibodies (eBiosciences unless otherwise noted): CD3e
(145-2C11), CD45R (RA3-6B2, B220), CD11c (N418), Flk2 (A2F10), CD27 (LG.7F9), IL-7Ra
(gift of Deepta Bhattacharya, Washington University), Ly6D (49-H4, BD Biosciences), NK1.1
(PK136), IgM (II/4), IgD (11-26c), CD19 (eBio1D3), CD43 (S7, BD Biosciences), TER-119,
CD45 (30-F11), and CD31 (390).

Stromal cell analysis. To extract bone marrow stromal cells, femurs and tibias were crushed
with a mortar and pestle in phosphate buffered saline (PBS). Cells in suspension were collected
and stored on ice while bone chips and aggregates were digested using collagenase type II
(3mg/mL, Worthington Biochemical) and dispase (4mg/mL, Roche) at 37°C for 1 hour in a
shaking water bath. Following digestion both fractions were pooled, red blood cells lysed, and
analyzed. CAR cells were defined as CD45 - TER119- CD31- GFPbright cells in mice carrying the
Cxcl12gfp transgene. Cre-targeted cells were defined as TdTomato+ cells in mice carrying the loxstop-lox-TdTomato Ai9 transgene.

Immunostaining of bone sections. Femurs and tibias were harvested and fixed for 16-24 hours
in 4% paraformaldehyde (Sigma-Aldrich) at 4oC. Bones were washed twice in PBS, decalcified
in 14% ethylenediaminetetraacetic acid (EDTA) pH 7.4 solution for 3-5 days, and cryoprotected
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in 30% sucrose in PBS for 16-24 hours. Bones were then snap frozen in OCT media (TissueTek), and tissue blocks were sectioned (10 µm or 100 µm) using the CryoJane (Leica
Biosystems). Antibodies used included: goat anti-mouse VE-Cadherin (R&D Systems AF1002),
rat anti-mouse IgD (BD Biosciences clone 11-26c.2a), rat anti-mouse B220 (BD-Biosciences
RA3-6B2), rat anti-mouse IgM (eBioscience II/4), and mouse anti-alpha smooth muscle actin
(Sigma Aldrich 1A4). Sections were washed in TNT buffer (0.1 M Tris-HCl, 0.15 M NaCl,
0.05% Tween-20) and mounted with Prolong Gold Antifade Reagent (Invitrogen). Slides were
imaged using a LSM 700 confocal microscope and ZEN imaging software (Zeiss).

Mature B cell homing assay. Spleens were harvested from 8-12 week old CAG-GFP mice and
dissociated into a single cell suspension. 5 million splenocytes were injected retro-orbitally into
Cxcl12flox/- or OC-Cre Cxcl12flox/- mice. Recipients were harvested 24 hours after transplantation,
and GFP+ mature naïve B cell number was quantified in the bone marrow and spleen via flow
cytometry.

Statistics. Significance was determined using Prism software (GraphPad). Unless otherwise
stated, statistical significance of differences was calculated for two groups using Students t-test
and 3 or more groups using 1- or 2-way ANOVA. P-values less than 0.05 were considered
significant. All data are presented as mean ± SEM.
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3.3. RESULTS
3.3.1. Specific stromal cell populations regulate distinct stages of B cell development.
To determine the role CXCL12 from different bone marrow stromal cells plays in B
lymphopoiesis, we used a transgenic mouse line generated in our lab carrying a floxed Cxcl12
allele, allowing conditional deletion of Cxcl12 in specific stromal cell populations. Cxcl12flox
mice were crossed with mice expressing different Cre recombinases to target different stromal
cell populations. Deletion of Cxcl12 within endothelial cells using Tie2-Cre134 did not affect
baseline bone marrow B lymphopoiesis. Prx1-Cre was used to conditionally delete Cxcl12 in
mesenchymal stem cells and their downstream progeny70,132, including CAR cells, osteoblasts,
and osteocytes. Deletion of Cxcl12 in Prx1-Cre-targeted cells almost completely ablated bone
marrow CXCL12 mRNA production and severely reduced bone marrow white blood cell count
and B cell number (Figure 3.1A, 3.1B, & 3.1C). All stages of bone marrow B cell development
were reduced, beginning at the common lymphoid progenitor (CLP) stage of lymphopoiesis
(Figure 3.1C & 3.1D). Osterix-Cre (Osx-Cre) was used to delete Cxcl12 in CAR cells and their
downstream progeny70,133, resulting in a severe decrease in bone marrow CXCL12 mRNA
expression and bone marrow cellularity. Osx-Cre Cxcl12flox/- mice have normal numbers of CLPs
and B-committed lymphoid progenitor (BLPs) but have reduced number of bone marrow B cells
beginning at the pre-pro-B stage of B lymphopoiesis. Osteocalcin-Cre (OC-Cre) was used to
delete Cxcl12 in osteolineage cells86. Deletion of Cxcl12 using OC-Cre did not significantly alter
overall bone marrow CXCL12 expression, suggesting that osteolineage cells do not contribute
significantly to bulk CXCL12 production in the bone marrow. However, despite the relatively
minor contribution of osteolineage cells to overall CXCL12 production in the bone marrow,
deletion of Cxcl12 using OC-Cre resulted in a significant loss of mature naïve B cells in the bone
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marrow. These data suggest that CXCL12 supports B cell development in a stage- and stromalcell specific fashion. CXCL12 production from MSCs is important for CLPs, CXCL12 from
CAR cells is required for the generation of early B lymphoid cells, CXCL12 production from
osteolineage cells is required to maintain mature naïve B cell number in the bone marrow, and
CXCL12 from endothelial cells is dispensable for baseline B cell development.

3.3.2. OC-Cre-deletion of Cxcl12 does not affect bone marrow dendritic cell number
Perivascular dendritic cells have been reported to be a niche cell supporting mature naïve
B cell number in the bone marrow. Ablation of dendritic cells results in decreased mature B cell
survival in the bone marrow but does not affect homing93. To determine if loss of dendritic cells
is responsible for the observed decrease in bone marrow mature naïve B cell, we enumerated
CD11c+ dendritic cells in the bone marrow of OC-Cre Cxcl12flox/- mice relative to control mice.
We detected no difference in bone marrow dendritic cell number (Figure 3.2), indicating that
deletion of Cxcl12 in OC-Cre-targeted cells does not result in decreased dendritic cells.

3.3.3. CXCL12 expression in OC-Cre-targeted cells is required for efficient homing of
mature B cells to the bone marrow.
Mature naïve B cells home to the bone marrow after undergoing maturation in peripheral
lymphoid organs. The number of mature B cells in the spleen of OC-Cre Cxcl12flox/- mice is
comparable to control mice (Figure 3.3A), suggesting that the loss of mature B cells in the bone
marrow of OC-Cre Cxcl12flox/- mice is not due to defective peripheral maturation. We examined
the localization of mature B cells in the bone marrow of wild type and OC-Cre Cxcl12flox/- mice
to determine if mature B cells had an altered localization due to loss of CXCL12 derived from
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OC-Cre-targeted cells. As previously reported, mature B cells are predominantly localized to
perivascular niches in the bone marrow, and we detected no major mature B population in direct
contact with osteoblasts. Though markedly reduced in number, mature B cells in OC-Cre
Cxcl12flox/- animals exhibit similar perivascular localization (Figure 3.3B). We next examined the
homing of mature B cells to the bone marrow. Splenocytes from CAG-GFP mice, which
ubiquitously express GFP, were adoptively transferred into Cxcl12flox/- and OC-Cre Cxcl12flox/mice, and the number of GFP+ mature B cells in the bone marrow and spleen was assessed 24
hours later (Figure 3.3C). Homing of mature B cells to the bone marrow, but not to the spleen,
of OC-Cre Cxcl12flox/- mice was significantly impaired compared with control mice (Figure
3.3D). Interestingly, of the mature B cells that did home to the bone marrow, their localization to
perivascular regions was similar in Cxcl12flox/- compared to OC-Cre Cxcl12flox/- recipient mice
(Figure 3.3E). Together, these data show that CXCL12 expression from OC-Cre-targeted cells
plays a key role in the homing and/or retention of mature B cells in the bone marrow.

3.3.4. Autocrine CXCL12-CXCR4 signaling in OC-Cre-targeted cells is not required for
normal B lymphopoiesis.
CXCR4 signaling is required for normal osteoblast function135, and deletion of Cxcr4
within osteolineage cells has been shown to affect hematopoiesis. To test the hypothesis that loss
of autocrine CXCL12-CXCR4 signaling in the OC-Cre-targeted compartment is responsible for
decreased mature naïve B cell homing, we generated OC-Cre Cxcr4flox/flox mice to conditionally
delete Cxcr4 from cells expressing OC-Cre. We detected no alteration in mature naïve B cell
number in the bone marrow (Figure 3.4), indicating that autocrine CXCL12-CXCR4 is not
essential for mature naïve B cell homing to the bone marrow.
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3.3.5. OC-Cre targets osteocytes, osteoblasts, central marrow cells, and perivascular
arteriolar smooth muscle cells
Osteocalcin expression is highest in mineralizing osteoblasts but OC-Cre has been
reported to target central marrow stromal cells as well86. To better describe the cell populations
targeted by OC-Cre, we performed lineage mapping studies using Ai9 fluorescent reporter mice.
Recombination was observed in osteocytes, endosteal osteoblasts, scattered central marrow cells,
and periarteriolar alpha smooth actin-positive pericytes (Figure 3.5A & 3.5B). To determine if
OC-Cre-targeted central marrow cells overlapped with CAR cells, we generated triple-transgenic
OC-Cre Cxcl12-Gfp Ai9 mice. While there is substantial overlap between OC-Cre-targeted cells
and CAR cells (68.8 ± 4.7% of CAR cells are TdTomato +), a significant minority of CAR cells
are not targeted by OC-Cre (30.9 ± 5.2%) (Figure 3.6A, 3.6B, & 3.6C). Similarly, most Ai9 cells
are CAR cells (59.3 ± 8.3%), but a significant percentage of Ai9 + cells are GFP - (30.6 ± 8.9%) or
GFPintermediate (9.8 ± 0.1%) (Figure 3.6A, 3.6B, and & 3.6D), indicating that OC-Cre targets
some, but not all, CAR cells as well as a population of GFP intermediate stromal cells.

3.3.6. CXCL12 production from osteoblasts and osteocytes is not required for normal B
lymphopoiesis
Osteoblasts and osteocytes are known to play an important role in B lymphopoiesis 76,81–
83

. To test if CXCL12 from osteoblasts and osteocytes is responsible for the B cell phenotype

observed in OC-Cre Cxcl12flox/- mice, we used Dmp1-Cre to delete Cxcl12 in mature osteoblast
populations. While Dmp1-Cre was originally described to target osteocytes embedded in bone
matrix136, recent reports suggest that Dmp1-Cre also targets endosteal osteoblasts137,138. To
determine which cell types are targeted by Dmp1-Cre, we performed lineage mapping studies.
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As previously reported, Dmp1-Cre efficiently recombined in osteocytes and endosteal
osteoblasts. Surprisingly, we also found that Dmp1-Cre targeted scattered central marrow cells
(Figure 3.7A), indicating that Dmp1-Cre targets more broadly than has previously been reported.
In contrast to OC-Cre, however, perivascular smooth muscle cells were very rarely targeted. The
number of mature naïve B cells in the bone marrow was unaffected in Dmp1-Cre Cxcl12flox/mice (Figure 3.7B), indicating that CXCL12 production from endosteal osteoblasts and
osteocytes is not essential for mature naïve B cell homing.

3.3.7. G-CSF suppresses B lymphopoiesis, in part, in a CXCL12 independent fashion
In Chapter 2, we show that G-CSF decreases B cell number in the bone marrow. While
decreased CXCL12 production by stromal cells clearly contributes to G-CSF-induced B cell
suppression, it is unclear whether the loss of B cells is entirely attributable to decreased CXCL12
expression. To address this issue, we analyzed the effect of G-CSF treatment on Prx1-Cre
Cxcl12flox/- or control mice. Of note, CXCL12 mRNA production in Prx1-Cre Cxcl12flox/- mice is
nearly undetectable, thus any change in B cell number induced by G-CSF likely would be
CXCL12 independent. In control mice, G-CSF treatment resulted in a significant decrease in
bone marrow B cells. As noted already, the basal number of B cells in the bone marrow of Prx1Cre Cxcl12flox/- mice was significantly reduced. However, B cell number was further reduced
with G-CSF treatment in these mice (Figure 3.8). Thus, G-CSF treatment acts in both a
CXCL12-dependent and CXCL12-independent fashion to suppress B lymphopoiesis.

3.4. DISCUSSION
Previous studies have demonstrated the importance of CXCL12 in B lymphopoiesis.
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Mice deficient for CXCL12 or its primary receptor, CXCR4, have decreased B cell number in
the bone marrow beginning prior to pre-pro-B stage, due in part to reduced retention of
developing B cells in the bone marrow13–15,19,203–16. Chimeric mice and conditional deletion of
Cxcr4 show that CXCL12 from the stromal compartment is required for normal B lymphopoiesis
and for mature B cell localization to the bone marrow18. Within the bone marrow, CXCL12 is
produced by multiple different stromal cell populations, including mesenchymal stem cells, CAR
cells, osteoblasts, and endothelial cells 63,66,70,73,74,79,131, and some of these populations are known
to play important roles in B lymphopoiesis. Pre-pro-B cells have been reported to localize to
CXCL12-expressing CAR cells in bone marrow63, and ablation of CAR cells results in decreased
CLP number, decreased pro-B proliferation, and increased pro-B apoptosis74. Disruption of the
transcription factor Foxc1 disrupts CAR cell osteogenic potential, downregulates CXCL12
production, and inhibits B lymphopoiesis75. Osteoblasts can support B cell proliferation and
differentiation in vitro, and ablation of osteoblasts or conditional deletion of signaling molecules
within osteoblasts can disrupt B lymphopoiesis76,81,82. Osteocytes have also been implicated in
the regulation of bone marrow B cell development via production of sclerostin, important for B
cell survival83. The specific role of CXCL12 within these populations on B lymphopoiesis,
however, has not previously been reported.
We show that CXCL12 expression from mesenchymal progenitors is required for
maintenance of CLP number, while CXCL12 from CAR cells is not required until the pre-pro-B
cell stage of B cell differentiation. Our data also show that CXCL12 expression from OC-Cretargeted cells is required to maintain the reservoir of mature naïve B cells in the bone marrow via
homing from the peripheral circulation and retention in the bone marrow. These results are
somewhat surprising, since CXCL12 production from osteoblasts/osteocytes is a minor
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contributor to bulk CXCL12 production in the bone marrow. Because dendritic cells are known
to be important for mature B cell survival in the bone marrow 93, we examined dendritic cell
number in OC-Cre Cxcl12flox/- mice and detected no change in dendritic cell number. A recent
study showed that deletion of Cxcr4 in mature osteoblasts resulted in impaired osteoblast
function135, suggesting that CXCL12 production by osteoblasts/osteocytes may act in an
autocrine fashion to regulate function. Autocrine CXCL12-CXCR4 signaling within the OCCre-targeted compartment in not required for mature naïve B cell homing, however, since no
defect is observed in OC-Cre Cxcr4flox/flox mice. Further research is required to understand how
CXCL12 from OC-Cre-targeted cells results in decreased mature B cell homing and retention,
whether through a direct mechanism of CXCL12 from the OC-Cre-compartment interacting with
CXCR4 on mature recirculating B cells, or via an indirect mechanism.
Although prior studies suggested that OC-Cre specifically targeted mature osteoblasts
and osteocytes86, our lineage-mapping studies show that OC-Cre targets osteocytes, osteoblasts,
central marrow cells, and periarteriolar smooth muscle cells. Deletion of Cxcl12 within
osteoblasts and osteocytes using Dmp1-Cre did not affect mature naïve B cell number in the
bone marrow, indicating that CXCL12 from these populations is not required for mature naïve B
cell homing. Dmp1-Cre does not target periarteriolar smooth muscle cells, however, a
compartment that is targeted by OC-Cre. Periarteriolar smooth muscle cells have not previously
been described to play a role in B lymphopoiesis, but recent evidence has emerged suggesting
they may play a role in stem cell maintenance. It has also been reported that they express high
levels of CXCL12 and KITL85, known to be important for bone marrow B cell development,
suggesting that they may play a role in bone marrow B lymphopoiesis, and loss of CXCL12
within this population may be sufficient to result in impaired mature B cell homing to the bone
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marrow. Central marrow cells targeted by OC-Cre could also be responsible for the homing
defect observed in OC-Cre Cxcl12flox/- mice. While both OC-Cre and Dmp1-Cre target a reticular
central marrow stromal cell population, it is currently unknown if the cell type, cell number, and
extent of targeting is similar in the two models. Further study will be needed to rule out the
possibility that CXCL12 produced by these central marrow cells is responsible for mature naïve
B cell homing.
A study on an independent Cxcl12 conditional deletion mouse model provides
complementary insight on the role of CXCL12 from different stromal cell populations on B
lymphopoiesis. In that study, Col2.3-Cre was used to delete Cxcl12 in osteoblasts. Lineage
mapping data was not reported, so it is unknown to what extent Col2.3-Cre overlaps with OCCre or Dmp1-Cre. Under baseline conditions, CLP number was decreased but downstream
committed B cells, including pre-pro-B, pro-B, and pre-B cells, were normal in number. Mature
naïve B cell number was not enumerated. Lin- IL-7Ra+ cells, a population enriched for CLP and
lymphoid-primed multipotent progenitors, were reported by immunofluorescence to be enriched
at the endosteum, suggesting that endosteal osteoblasts may play a special role in maintaining
CLP, and that in spite of low CLP number, CXCL12 from other niches is sufficient to normalize
later stages of B cell development. Upon transplant into irradiated wild type recipients, Col2.3Cre Cxcl12flox/flox bone marrow had significantly reduced contribution to B cell lineage relative to
control cells, suggesting reduced B cell potential as late as 16 weeks post-transplant73. It is
unclear why a deficit in B lymphopoiesis would be maintained after transplant into an
environment expressing wild type levels of CXCL12 when B cell number is normal Col2.3-Cre
Cxcl12flox/flox mice. It is possible that stress induced by transplant is sufficient to overwhelm the
compensatory mechanisms that are sufficient to normalize B cell number under non-transplant
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conditions. In the same study, Lepr-Cre was used to delete Cxcl12 in CAR cells. In contrast to
Osterix-Cre, no loss of bone marrow B cells was observed. The discrepancy may be due to wider
targeting in Osterix-Cre mice, where osteoblasts, osteocytes, and periarteriolar smooth muscle
cells are targeted, whereas these populations were not targeted in Lepr-Cre mice at the time the
mice were analyzed, or different targeting efficiency within the CAR cell compartment.
Our data are consistent with a model of B lymphopoiesis in which developing B cells in the
bone marrow interact with different stromal cell niche populations as the B cells differentiate.
Data supporting this model comes from multiple different groups reporting that bone marrow B
cells at different stages of differentiation are in contact with different stromal cell populations,
including data suggesting that CLPs are in contact with endosteal osteoblasts73, pre-pro-B cells
are in contact with CAR cells, pro-B cells are in contact with IL-7-expressing cells63, late pre-B
cells are in contact with Galectin-1-expressing cells64, and mature naïve B cells are in contact
with dendritic cells93. In this model, our data would suggest that CXCL12 provided by MSCs is
essential for CLP maintenance, CXCL12 from CAR cells is important for pre-pro-B cell
development, and CXCL12 from an OC-Cre-compartment is required for mature naïve B cell
homing. Because bulk CXCL12 levels are different in each of our mouse models, however, our
data are also consistent with an alternative model in which different B cell populations are
differentially sensitive to overall bone marrow CXCL12 level. In this model, mature naïve B cell
homing are sensitive to modest reductions in overall bone marrow CXCL12 level, pre-pro-B
cells are sensitive to an intermediate reduction in overall bone marrow CXCL12 level, and CLPs
are sensitive only to a severe reduction in total bone marrow CXCL12. A rescue experiment in
which overall CXCL12 level in the bone marrow is restored from a non-physiologic source or
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where CXCL12 expression is restored in some but not all niche populations could distinguish
between these models.
Stromal cells in the bone marrow are currently poorly understood, and dissecting the
identity of the cells differentially targeted, and their relationship to one another, has the potential
to clarify the nature of the bone marrow microenvironment. Lineage mapping of OC-Cre Ai9
Cxcl12-Gfp mice showed that the OC-Cre-targets multiple stromal cell populations, including
GFPintermediate and GFP- cell populations. Comparison with similar populations in Dmp1-Cre Ai9
Cxcl12-Gfp mice or surface phenotyping may provide clues as to the identity of these cells. The
targeted compartment in OC-Cre mice also included some, but not all, CAR cells. The biological
relevance of these results is not currently known. Since CAR cells are a multipotent osteogenicadipogenic population, it is possible that CAR cells targeted by OC-Cre have committed to the
osteoblastic lineage, representing an intermediate stage between CAR cells and osteoblasts. OCCre-targeted CAR cells could also represent a distinct lineage from non-targeted CAR cells,
however. Periarteriolar smooth muscle cells have also been reported to be an osteoprogenitor
population84, and our lineage mapping data are consistent with that model. CAR cells and
periarteriolar smooth muscle cells may represent two independent methods of generating
osteoblasts, or one population could be descended from the other. Based on lineage mapping
data, if CAR cells and periarteriolar cells are related, CAR cells are likely descended from
periarteriolar cells rather than the converse, since OC-Cre targets periarteriolar cells and some
central marrow CAR cells, while Dmp1-Cre efficiently targets central marrow cells but not
periarteriolar cells. This model is also consistent with data indicating that Lepr-Cre targets CAR
cells and osteoblasts but not periarteriolar smooth muscle cells71.
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These data show that CXCL12 derived from distinct bone marrow stromal cells has a
differential effect on bone marrow B lymphopoiesis. Clarifying which stromal cell populations
regulate B cell development has potential relevance to human disease. CXCL12 is known to be
an important niche factor regulating B cell diseases corresponding to different stages of B cell
development. CXCL12 is known to be an important bone marrow niche component for B-ALL,
the most common subset of which corresponds to the pre-B stage of B lymphopoiesis, while
activating CXCR4 mutations are common in lymphoplasmacytic lymphoma and IgM-MGUS,
corresponding to later stages of B cell maturation31,118–122. Understanding which stromal cells
provide CXCL12 crucial for the maintenance of these different populations opens the possibility
of developing targeted therapy to disrupt interactions between malignant cells and their niches
while limiting toxicity to non-malignant B cells and other bone marrow niches.

3.5 ACKNOWLEDGEMENTS
We thank Jill Woloszynek, Amy Schmidt, and Molly Romine for technical assistance, Jackie
Tucker-Davis for animal care, William Eades, Jackie Hughes, and Dan Schweppe for cell sorting
assistance, Dr. Thomas Clemens for the OC-Cre mice, Dr. Roberto Civatelli for the Dmp1-Cre
mice, and Dr. Robin Klein for the Cxcr4flox mice. Microscopy imaging support was provided by
Angie Schrader and the Microscopy and Digital Imaging Core of the Research Center for
Auditory and Vestibular Studies, NIH P30DC004665. This work was supported by NIH grants
GM07200, RO1 HL60772 (DCL) and F30 HL112552-02 (RBD).

67

3.6 AUTHOR CONTRIBUTIONS
Ryan B. Day designed and performed the research, analyzed the data, and wrote the manuscript.
Michael Zhang assisted in the analysis of Dmp1-Cre Cxcl12flox and OC-Cre Cxcr4flox mice.
Adam Greenbaum generated the Cxcl12flox mice and contributed some data to the CXCL12 RNA
expression analysis. Deepta Bhattacharya provided technical assistance and assisted with data
analysis. Takashi Nagasawa provided the Cxcl12-Gfp mice. Daniel C. Link supervised all of the
research and edited the manuscript.

3.7. PUBLICATION
Part of this work was published in: Greenbaum A, Hsu YM, Day RB, Schuettpelz LG,
Christopher MJ, Borgerding JN, Nagasawa T, Link DC. 2013. CXCL12 in early mesenchymal
progenitors is required for haematopoietic stem-cell maintenance. Nature, 495(7440):227-30.

68

3.8 FIGURES

Figure 3.1. Loss of stromal cell production of CXCL12 results in impaired B lymphopoiesis.
A. Femurs from mice with the indicated genotypes were flushed with Trizol to extract total bone
marrow RNA. Shown is the expression of CXCL12 mRNA relative to -actin. B. The number
of the indicated progenitor or B-cell subset in the bone marrow of Cxcl12fl/-, Tie2-Cre Cxcl12fl/-,
OC-Cre Cxcl12fl/-, Osx-Cre Cxcl12fl/-, or Prx1-Cre Cxcl12fl/- mice was enumerated by flow
cytometry C & D. The number of the indicated progenitor or B-cell subset in the bone marrow of
Cxcl12fl/-, Tie2-Cre Cxcl12fl/-, OC-Cre Cxcl12fl/-, Osx-Cre Cxcl12fl/-, or Prx1-Cre Cxcl12fl/- mice
was enumerated by flow cytometry. Data represent the mean ± SEM of 5-37 mice. *P < 0.05;
**P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 3.2. Cxcl12 deletion in OC-Cre-targeted cells does not affect dendritic cell number.
Shown is the bone marrow frequency (left panel) or absolute number (right panel) of CD11c+
dendritic cells in the bone marrow of Cxcl12fl/- or OC-Cre Cxcl12fl/- mice. Data represent the
mean ± SEM of 7-15 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 3.3. Homing of mature B cells to the bone marrow is impaired in OC-Cre Cxcl12flox/mice. A. The number of mature (Fraction F) B cells in the spleen of mice of the indicated
genotypes is shown. B. Representative photomicrographs showing the localization of mature B
cells in the bone marrow of wild type (left panel) or OC-Cre Cxcl12flox/- mice (right panel). IgD
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expressing mature B cells (green) and VE-cadherin+ endothelial cells (red) are shown. Scale bar:
100 µm. C. Splenocytes (5 x 106) from CAG-GFP mice were injected intravenously into OCCre Cxcl12flox/- or control mice. D. Shown is the number of GFP+ mature B cells in the bone
marrow (left panel) and spleen (right panel) and 24 hours after injection. Data represent the
mean ± SEM of 11-16 mice. *P < 0.05; ns: non-significant. E. Representative photomicrographs
showing the localization of homed Fraction F cells in the bone marrow of Cxcl12flox/- (left panel)
or OC-Cre Cxcl12flox/- mice (right panel). GFP expressing cells (green), IgD expressing mature B
cells (red), and VE-cadherin+ endothelial cells (blue) are shown. Arrows indicate cells coexpressing GFP and IgD. Scale bar: 100 µm.
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Figure 3.4. Autocrine CXCL12-CXCR4 signaling in OC-Cre-targeted cells is not required for
normal B lymphopoiesis. Shown is the bone marrow frequency (left panel) or absolute number
(right panel) of CD11c+ dendritic cells in the bone marrow of Cxcl12fl/- or OC-Cre Cxcl12fl/mice. Data represent the mean ± SEM of 7-8 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns:
non-significant.
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Figure 3.5. OC-Cre targets osteocytes, osteoblasts, central marrow cells, and periarteriolar
smooth muscle cells. A. Representative photomicrographs of OC-Cre Ai9 lineage mapping mice
showing cells targeted by OC-Cre (red). DAPI is blue. B. Representative photomicrographs
showing colocalization of OC-Cre-targeting (red) and smooth muscle actin staining (green). C.
Representative photomicrograph showing OC-Cre-targeting (red), smooth muscle actin staining
(green), and endothelial staining (VE-Cadherin, blue). Scale bar: 100 µm
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Figure 3.6. OC-Cre targets a subpopulation of CAR cells. A. Representative photomicrographs
of OC-Cre Ai9 Cxcl12-Gfp lineage mapping mice showing cells targeted by OC-Cre (red) and
expressing Cxcl12-Gfp (green). Scale bar: 100 µm. B. Representative flow cytometry plot
showing CXCL12GFP expression (x axis) and OC-Cre targeting (y axis). Cells were gated on
CD45- Ter119- CD31-. C. Quantification of the number of OC-Cre-targeted CAR cells (left
panel) and frequency of CAR cells within the OC-Cre-targeted population (right panel). Data
represent the mean ± SEM of 2 mice.
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Figure 3.7. CXCL12 expression is osteocytes and osteoblasts is not required for mature B cell
homing. A. Representative photomicrographs of Dmp1-Cre Ai9 lineage mapping mice showing
cells targeted by Dmp1-Cre (red) and expressing smooth muscle actin (green). Scale bar: 100
µm. B. Quantification of bone marrow mature B cell number (left panel) and frequency (right
panel) in Cxcl12fl/- or Dmp1-Cre Cxcl12fl/- mice. Data represent the mean ± SEM of 5-13 mice.
*P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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Figure 3.8. G-CSF-induced B cell suppression occurs, in part, via CXCL12-independent
pathways. Mice of the indicated genotype were treated for 5 days with G-CSF or PBS, and the
number of bone marrow B cells was quantified by flow cytometry. Data represent the mean ±
SEM of 3-19 mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns: non-significant.
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS

The primary goal of this work was to understand how the stromal bone marrow
microenvironment regulates B lymphopoiesis. We took two approaches to examine the
interactions between developing B cells and stromal cells. In Chapter 2, we examined how GCSF regulates bone marrow stromal cells to decrease bone marrow B cell number. In Chapter 3,
we used a Cxcl12 conditional deletion model to dissect the role CXCL12 provided from different
stromal cell populations plays in B lymphopoiesis. These questions have potential clinical and
basic science relevance. Regulation of stromal cell function, the lineal relationship between
different stromal cells, and how stromal cells interact with different hematopoietic populations in
the bone marrow are poorly understood, and clarification provides insight into basic biology. The
stromal niche has also been implicated in the maintenance of malignant cells in the bone marrow,
and understanding how to modulate the supportive signals provided by stromal cells may point to
new therapeutic regimens.

4.1. G-CSF reprograms the bone marrow microenvironment to suppress B lymphopoiesis
4.1.1. Summary
In Chapter 2, we explored how G-CSF affects stromal cells to suppress bone marrow B
cell development. We showed that G-CSF works through cells of the monocyte-macrophage
lineage to reprogram CAR cells, suppressing their adipogenic potential while downregulating
their expression of B trophic factors. We also show that G-CSF decreases the number of mature
osteoblasts in the bone marrow and downregulates the expression of B trophic factors in the
remaining osteoblasts. These cumulative effect of these changes is severely impaired B
lymphopoiesis. B cell number is decreased at all stages of bone marrow development, from the
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BLP stage to the mature naïve B cell stage. The loss of B cells in the bone marrow is attributed
in part to mobilization of early fraction B cells to the spleen where they undergo high rates of
apoptosis, and in part to apoptosis in the bone marrow directly.

4.1.2. Can G-CSF synergize with chemotherapy in a mouse model of B-ALL?
Several lines of evidence indicate that the bone marrow microenvironment can shelter
malignant cells from conventional chemotherapy. Niche factors have been reported to promote
quiescence, associated with chemoresistance, in B-ALL cells119,122. Our results indicate that GCSF promotes B cell cycling, and if G-CSF similarly induces cycling in malignant cells, it may
be able to chemosensitize malignant blasts. The CXCL12-CXCR4 inhibitor AMD3100 has been
shown to synergize with conventional chemotherapy in mouse models of B-ALL120. G-CSF
disrupts B lymphopoiesis in part by downregulating CXCL12 expression in CAR cells and
osteoblasts, suggesting that G-CSF may also be able to chemosensitize malignant cells. G-CSF
affects multiple other B trophic factors besides CXCL12, including KIT ligand, IL-6, IL-7,
FLT3L, BAFF, and IGF-1. Because G-CSF targets a broader range of B trophic factors, it may
provide a more effective tool than the more narrowly-targeted AMD3100. To test this
hypothesis, we have an ongoing study in which a B-ALL cell line engineered to express
luciferase is injected into immunocompromised mice. After engraftment, mice are treated with
chemotherapy, with or without G-CSF. Survival and tumor burden, as assessed by luciferase
signal, are assessed over time. Correlative studies for cell cycling, apoptosis, and mobilization of
blasts could also be performed to provide additional mechanistic insight. Future studies could
involve the use of primary patient samples to determine if certain tumor profiles are more likely
to be sensitive to G-CSF treatment.
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4.1.3. What effect does G-CSF have on -smooth muscle actin-positive pericytes?
Periarteriolar -smooth muscle actin pericytes have recently been shown to be an
important stromal cell population modulating hematopoietic stem cell quiescence 85. Evidence
from our Cxcl12 conditional deletion model (Chapter 3) suggests that these pericytes may also
play a role in B cell maintenance in the bone marrow, specifically the homing or retention of
mature naïve B cells in the bone marrow. G-CSF treatment decreases mature naïve B cell
number in the bone marrow. In part, this is due to increased mature B cell apoptosis, likely due
to G-CSF-induced loss of dendritic cells in the bone marrow. Homing studies also indicate that
mature naïve B cells do not home to the bone marrow of G-CSF-treated mice, similar to the
phenotype observed in OC-Cre Cxcl12flox/- mice. Of note, expression of the E-mu-Bcl2 transgene
fails to rescue mature naïve B cell number in the bone marrow of G-CSF-treated mice. These
data suggest that G-CSF treatment also results in an inability of mature naïve B cells to home or
be retained in the bone marrow. Whether G-CSF has any effect on pericytes is not currently
known, however. To examine the effect of G-CSF on pericytes, RNA expression profiling of
pericytes from PBS versus G-CSF-treated mice could be performed. Identification of pericytes
by flow cytometry is currently challenging. Anti--smooth muscle actin antibodies exist but
require cell fixation and permeabilization which could complicate RNA extraction and yield.
Endogenous reporters may provide an easier way to label, count, and sort pericytes. We have
attempted to use Myh11-Cre, a Cre recombinase driven by the smooth muscle myosin light chain
promoter, bred into a lineage mapping strain to identify -smooth muscle actin-expressing
pericytes in the bone marrow. Despite efficiently labeling smooth muscle cells, including
vascular smooth muscle cells, in other organs (Figure 4.1A), Myh11-Cre failed to consistently or
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predictably target bone marrow pericytes (Figure 4.1B). We have obtained Transgelin-Cre mice,
expressing a Cre recombinase reported to be expressed in vascular smooth muscle cells. While
expression of Transgelin-Cre in bone marrow vascular smooth cells has not been reported, a
recent report has shown expression of Transgelin protein in bone marrow vascular smooth
muscle pericytes71. Since the Transgelin-Cre is knocked-in to the endogenous Transgelin locus,
expression of the Cre recombinases should faithfully reflect expression of the protein.
Alternatively, Sma-Gfp reporter mice exist 84 and could also be used to label and sort pericytes
with or without G-CSF exposure.

4.1.4. How does G-CSF treatment change CAR cell number and potential?
In our study, we observed an increase in CAR cell number. It is not currently known if
CAR cells themselves are proliferating or if MSCs are proliferating to increase CAR cell
number. Likewise, it is not known if the shift towards osteogenic differentiation in CAR cells is
due to existing multipotent CAR cells differentiating down an osteogenic path, or if MSCs are
producing CAR cells already committed to an osteoblastic fate. Distinguishing between these
two possibilities would help to clarify how G-CSF exerts its effects on stromal cells and could
point towards a role for G-CSF in MSC biology. These questions could be addressed in part by
cell cycle analysis of MSCs and CAR cells in PBS versus G-CSF-treated mice. While MSCs are
very rare and cell surface phenotypes are controversial, multiple mice could be pooled and
different surface phenotypes could be analyzed to assess the cycling status of MSCs after G-CSF
treatment. If G-CSF acts on MSCs, we would expect to see increased MSC cycling after G-CSF
treatment. The effect of G-CSF on CAR cell proliferation could be similarly analyzed. The effect
of G-CSF on the osteoblastic/adipogenic potential of MSCs could be tested by sorting MSCs
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from G-CSF-treated mice and performing CFU-F assays to analyze the osteogenic and
adipogenic activity of their progeny.
In G-CSF-treated mice, CAR cell number and osteogenic potential increases while
mature osteoblast number decreases. The increase in osteogenic CAR cells post-G-CSF
treatment could be a compensatory change due to this loss of osteoblasts, or it could be a direct
consequence of G-CSF signaling through monocytic cells. An osteoblast ablation model, such as
the Col2.3-Tk or Dmp1-Cre-iDTR, could be used to ablate osteoblasts in the absence of G-CSF
treatment to determine if a similar increase in osteogenic CAR cells is observed. The alterations
in hematopoiesis produced by osteoblast ablation81 may make such a model difficult to interpret,
however. An alternative approach would be to use a model overexpressing anti-apoptotic BCL2
in the osteoblast compartment. These models have their own drawbacks, however, including
impaired osteoblast differentiation and osteocyte function139.

4.1.5. How are CAR cells related to other reported stromal B niche populations?
CAR cells, osteoblasts, IL-7-expressing stromal cells, and Galectin-1-expressing stromal
cells have all been reported to be niche cells for bone marrow B cells. While some reports have
suggested that CAR cells, IL-7-expressing cells63, and Galectin-1-expressing cells64 are three
distinct stromal cell populations, the evidence presented thus far is not entirely convincing, and
by RNA expression CAR cells produce high levels of IL-7 and Galectin-1. It is possible that all
three cell populations are distinct, that all three cell populations are the same, or that there is
some overlap between the three. Recently developed tools allow the relationship between CAR
cells and IL-7-expressing stromal cells to be clearly defined. An Il7-Gfp knock-in mouse
strain91,92 should allow accurate visualization of IL-7 expression, overcoming the weaknesses of
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transgenic IL-7 reporter strains that contain fragments of the Il7 promoter and are randomly
inserted into the genome. While the Il7-Gfp allele could not be distinguished from Cxcl12-Gfp,
an alternate readout of CXCL12 expression could be used, such as Cxcl12-Dsred. Alternatively,
the only transgenic IL-7 reporter mouse reported to have bone marrow expression, Il7-Cfp88,
could be bred into the Cxcl12-Gfp background to distinguish the two cells provided endogenous
CFP expression is sufficient for imaging. Antibody staining for Galectin-1 would allow
quantification of the number of Galectin-1-expressing stromal cells that overlaps with CAR cells
and IL-7-expressing cells to clearly define the relationship between these cell types.
B cells in the bone marrow have been reported to interact with different stromal cells at
different stages of B cell development, with pre-pro-B cells interacting with CAR cells, pro-B
cells interacting with IL-7-expressing cells63, and early pre-B cells interacting with Galectin-1
cells64. One model of B cell development in the bone marrow suggests that a developing B cell
moves from one cell type to another as the B cell matures. If CAR cells, IL-7-expressing cells,
and Galectin-1 cells substantially overlap, it would provide evidence for a different model, that a
single stromal cell is capable of providing a niche for multiple stages of B cell development.
Such a model could get additional support from rigorously describing the relationship of
different B cell subpopulations to the stromal cell populations identified. Our
immunofluorescence assays are currently limited to 4 colors, restricting the number of markers
that can be used for a single image and thus the number of cell populations that can be identified.
We have successfully performed immunofluorescence for mature naïve B cells. Protocols for
pre-pro-B cells and pro-B cells have been reported in the literature63, but we have not been able
to successfully reproduce these results. Additional work to develop robust staining panels for
bone marrow B cell subsets will be necessary to describe the relationship of bone marrow B cells
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to stromal cells. Alternatively, other groups have performed adoptive transfers using sorted cells
to ask similar questions64, though these results are potentially confounded by sorting, bone
marrow homing, competition with similar cells in an unirradiated host, and a radically altered
microenvironment in an irradiated host.

4.2. CXCL12 from stromal cell populations regulates B cell development
4.2.1. Summary
In Chapter 3, we explored the role that CXCL12 from different stromal cell populations
plays in B cell development. Deletion of Cxcl12 in mesenchymal stem and progenitor cells using
Prx1-Cre resulted in almost total loss of bone marrow CXCL12 and a severe decrease in B cell
number beginning at the CLP stage of lymphopoiesis. Deletion of Cxcl12 in CAR cells using
Osx-Cre resulted in a major reduction in bone marrow CXCL12 and a defect in B cell
development beginning at the pre-pro-B stage. Deletion of Cxcl12 in osteolineage cells using
OC-Cre resulted in a minor change in total bone marrow CXCL12 level and decreased mature
naïve B cells in the bone marrow due to a homing or retention defect. Since Dmp1-Cre or Tie2Cre-mediated deletion of Cxcl12 produced no phenotype, we concluded that mature osteoblast or
endothelial-derived CXCL12 is dispensable for baseline B lymphopoiesis.

4.2.2. Is the decrease in mature naïve B cell number in OC-Cre Cxcl12flox/- mice due to
decreased homing or decreased retention?
Using an adoptive transfer model, we showed that fewer mature naïve B cells injected
into the peripheral blood can be detected in the bone marrow of OC-Cre Cxcl12flox/- animals
relative to control animals 24 hours post-injection. This decrease could be due to impaired
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homing from the peripheral blood/spleen to the bone marrow, or reduced retention of cells in the
bone marrow. To distinguish between these two possibilities, we are planning to do in vivo
imaging of our adoptive transfer model in collaboration with the Sipkins lab at Duke University.
By imaging in real time at an early time point after the adoptive transfer, we will be able to
determine how mature naïve B cells in the peripheral blood interact with the bone marrow. If
decreased mature B cell number is due to decreased homing, we expect to see fewer mature
naïve B cell exiting the peripheral blood and entering the bone marrow. If decreased retention is
responsible, mature B cells should transit into the bone marrow at similar rates in OC-Cre
Cxcl12flox/- and control mice but should not be retained in the bone marrow at the same rate. The
same question could also be addressed by repeating the adoptive transfer experiment and
sacrificing mice at various times prior to 24 hours.

4.2.3. What is the OC-Cre-targeted cell population that produces the CXCL12 required for
normal mature naïve B cell homing/retention?
OC-Cre targets multiple different stromal cell populations in the bone marrow, but it is
unclear which population is responsible for the loss of mature B cells in the bone marrow. By
immunofluorescence, we observed targeting of osteocytes, osteoblasts, central marrow cells, and
periarteriolar -smooth muscle cells. Dmp1-Cre also targets osteoblasts and osteocytes, and
since there is no loss of mature B cells in Dmp1-Cre Cxcl12flox/- mice, osteocytes and osteoblasts
are unlikely to be responsible for producing CXCL12 required for mature B maintenance in the
bone marrow. Both OC-Cre and Dmp1-Cre target a central marrow population. Flow cytometry
in an OC-Cre Ai9 Cxcl12-Gfp reporter mouse shows that the majority of these cells are CAR
cells, though notably there are untargeted CAR cells and targeted cells that are GFP intermediate as
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well. It is unknown if the central marrow cells targeted by Dmp1-Cre are also CAR cells, or if
the extent of targeting is the same. Dmp1-Cre Ai9 Cxcl12-Gfp mice could be generated and
compared to OC-Cre Ai9 Cxcl12-Gfp mice to determine if the populations are similar. If both
Dmp1-Cre and OC-Cre do target similar populations to the same extent, these central marrow
cells are also unlikely to be responsible for the mature B cell deficit. Lepr-Cre may also be useful
in resolving this question. Lepr-Cre targets all CAR cells71,73, and if Lepr-Cre Cxcl12flox/- mice
show no defect in bone marrow mature B cell number, CAR cells can be excluded as candidates.
Periarteriolar smooth muscle cells are targeted extensively by OC-Cre but only rarely
targeted by Dmp1-Cre and thus represent an attractive candidate for mediating the mature B cell
defect observed in OC-Cre Cxcl12flox/- mice. Our first attempt to target these cells using a Cre
recombinase driven by the smooth muscle myosin light chain promoter (Myh11-Cre) failed to
target these cells in the bone marrow (Figure 4.1). We have begun breeding a second smooth
muscle Cre line, Transgelin-Cre, into our lineage mapping and Cxcl12flox colonies to determine if
Transgelin-Cre will target our cells of interest. Because Transgelin protein expression has been
described in bone marrow periarteriolar smooth muscle cells71 and the Transgelin-Cre is a
knock-in into the endogenous Transgelin locus, we expect to see appropriate targeting. If the
Transgelin-Cre does not target appropriately, however, there are additional alternatives,
including both constitutive and inducible -Smooth Muscle Actin-Cre lines140,141 and the Ng2Cre line85. Because periarteriolar smooth muscle cells may be osteoprogenitors84, Transgelin-Cre
may target both smooth muscle cells and osteoblasts, making it difficult to prove that Cxcl12
deletion in periarteriolar smooth muscles alone, rather than the combination of loss in
periarteriolar smooth muscle cells and osteoblasts, is responsible for the loss of mature B cells. It
is also possible that the periarteriolar smooth muscle cell compartment contains MSCs, in which
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case targeting of CAR cells and other stromal cells may also be observed. If Transgelin-Cre does
target broadly, a Transgelin-DTR line142, allowing ablation of only cells currently expressing
Transgelin, has been reported and may be useful in providing correlative evidence for a specific
role of periarteriolar smooth muscle cells in mature B cell homing/retention.
Localization of mature B cells in the bone marrow may also help identify the cell type
that produces the CXCL12 required for mature B cell maintenance. While mature B cells have
been reported to be localized perivascularly and near dendritic cells93, their relationship with
bone marrow stromal cells has not been described. Localization of adoptively transferred mature
naïve B cells into an OC-Cre Ai9 Cxcl12-Gfp mouse may show a relationship to a particular
subset of OC-Cre-targeted cells, providing suggestive evidence of a role for that cell type in
mature B cell maintenance in the bone marrow.

4.2.4. What are the central marrow cells targeted by OC-Cre?
Because stromal cells in the bone marrow are currently poorly defined, dissecting the
nature of the cells targeted by OC-Cre may be useful in better understanding the stromal
microenvironment. Approximately 40% of the OC-Cre-targeted cells in crushed bone marrow
are not CAR cells, and it is unknown what they represent. They could include periarteriolar
smooth muscle cells, in which case co-staining with an antibody against -smooth muscle actin
or NG2 should produce costaining. They also may represent a stage of osteoblast development.
Costaining for an osteoblast marker such as ALCAM or Osteocalcin could be informative, and
sorting followed by CFU-F or CFU-OB culture could be used to demonstrate osteogenic activity.
Alternatively, an unbiased approach like gene expression profiling via gene chip or RNA-seq
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could be performed to probe the gene expression signatures of these different populations for
clues about their nature.
OC-Cre targets approximately two-thirds of CAR cells in the crushed bone marrow,
leaving one-third untargeted. In the literature, CAR cells have been described as a homogenous
population since the surface markers and transcripts examined thus far seem to be expressed at
similar levels in all CAR cells74. Our OC-Cre targeting data thus represent a heterogeneity in
CAR cells that has not been previously reported. Because OC-Cre is typically considered an
osteolineage marker, OC-Cre targeting within CAR cells may represent commitment to the
osteoblast lineage. Sorting followed CFU-F, CFU-OB, and CFU-adipocyte assays could be used
to test this hypothesis, as could flow cytometry for osteolineage markers. Sorting followed by
RNA expression analysis could also be used to examine the extent to which targeted CAR cells
vary from non-targeted CAR cells in their expression of adipogenic and osteogenic genes. OCCre Ai9 Cxcl12-Gfp mice could also be treated with G-CSF to determine if CAR cell number is
increased in the targeted compartment, the untargeted compartment, or both.

4.2.5. Are other non-malignant or malignant B cell populations affected by Cxcl12 deletion
in specific stromal cells?
CXCL12-CXCR4 signaling is known to play an important role in the homing and
engraftment of B cell populations not examined in our study. Both plasmablasts and plasma cells
require CXCR4 in order to home to the bone marrow, at least at early time points 20. The homing
and engraftment of malignant B cells is also regulated by CXCL1231,120. Examining the number
of plasmablasts and plasma cells in the bone marrow of conditional deletion mice, under baseline
conditions or following immunization, could provide insight into the cells responsible for
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mediating the maintenance of these cells in the bone marrow. Analysis serum immunoglobulin
level, both pre- and post-challenge, could reveal a defect in humoral immunity. Adoptive transfer
of B-ALL, CLL, or lymphoplasmacytic lymphoma cell lines or primary cells into conditional
deletion mice could reveal which compartment, if any, is specifically responsible for recruiting
malignant B cells to the bone marrow.

4.2.6. Is niche-specific expression of CXCL12 required for normal B lymphopoiesis, or is
total bulk level sufficient?
Our data indicate that deletion of Cxcl12 within different stromal cells results in impaired
B lymphopoiesis at different stages of development. Because the stromal cells we analyzed are
lineally related, however, our data also show progressive drops in total bone marrow CXCL12
level that correlate with phenotype severity. Two different models could explain our results. In
the first model, CXCL12 must be provided from a specific stromal cell population to a B cell at a
specific development stage. In this model, MSCs provide CXCL12 required for CLP
development. CXCL12 from CAR cells is required for pre-pro-B cells but not for CLPs, while
OC-Cre-targeted cells provide CXCL12 required for mature B cells but not earlier stages of B
lymphopoiesis. Because the B cell must be located in the proper niche in order to continue to
develop normally, CXCL12 from a different source cannot substitute for CXCL12 from the
appropriate niche cell. In the second model, different stages of B cells are differentially sensitive
to the total level of CXCL12 in the bone marrow. CLPs require only very low levels of total
CXCL12, and thus are affected by deletion of Cxcl12 in MSCs, which totally ablates CXCL12
expression in the bone marrow, but not by other Cre models which have higher levels of
remaining CXCL12. Pre-pro-B cells require intermediate levels of CXCL12, while mature B

89

cells are sensitive to even minor perturbations in total CXCL12 level. Understanding which of
these two models is correct is important since the idea of a “niche” is generally assumed to
require cell-cell contact. If CXCL12 from any bone marrow source is capable of regulating B
cell development as well as CXCL12 from a specific stromal cell, the commonly held view of
CXCL12 as a “niche molecule” in B lymphopoiesis may not be accurate.
The different models can be distinguished in two different ways. In the niche-specific
model, developing B cells would be expected to be physically near their putative niche cell.
Consistent with this model, pre-pro-B cells have been reported to be in contact with CAR cells63.
CLPs have been reported to be in contact with osteoblasts73, but their relationship to MSCs has
not been described. Likewise, mature B cells have been reported to be in perivascular dendritic
cell niches93, but their relationship to OC-Cre-targeted cells has not been reported. The second
way to distinguish between the two models is via a CXCL12 rescue experiment. Restoring bulk
levels of CXCL12 in a conditional deletion mouse, but having the CXCL12 come from a
different cell source than the cell type targeted by the deletion, would be expected to rescue the B
cell defect in model 2 but not model 1. We attempted to perform a rescue experiment by
transplanting hematopoietic cells infected with a CXCL12-overexpressing lentivirus into Prx1Cre Cxcl12flox/- recipients. However, we were unable to sufficiently restore total CXCL12 levels,
in part due to selection against CXCL12-infected hematopoietic cells relative to empty vectorinfected cells (Figure 4.2). One alternate approach could include using an inducible virus system
to reduce selection against CXCL12-infected hematopoietic cells. Alternatively, a transgenic
mouse model could be generated, restoring CXCL12 expression in CAR cells or osteoblasts on a
Prx1-Cre Cxcl12flox/- background, for example. Such a model could even be inducible. However,
no promoters have yet been identified that would be appropriate to drive high-level CXCL12 in a
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specific stromal cell population, and generation of the transgenic mice would be a timeconsuming and expensive endeavor.

4.3. Conclusion
In Chapter 2 of this thesis, we described how G-CSF suppresses B cell development in
the bone marrow. We show that G-CSF signals through monocyte lineage cells to alter the
expression of B trophic factors in supportive stromal cell populations, resulting in B cell
mobilization and apoptosis. We also show that G-CSF alters CAR cell potential, promoting
osteogenic differentiation over adipogenic differentiation. In Chapter 3 we explored the role
CXCL12 from different stromal cell populations plays in B lymphopoiesis. While CXCL12 from
endothelial cells and osteoblasts/osteocytes appears to be dispensable for baseline B
lymphopoiesis, CXCL12 from MSCs is required for CLP maintenance, CXCL12 from CAR cells
is required for pre-pro-B maintenance, and CXCL12 from OC-Cre-targeted cells is required for
mature B cell maintenance. These data help clarify how stromal cells interact with developing B
cell in the bone marrow, and how an exogenous factor can be used to alter hematopoiesis by
inducing microenvironmental changes. Though our studies were limited to non-malignant B cells
and limited stromal cell subsets, the results generated may provide insight into the broader
stromal cell microenvironment and may provide insights that are therapeutically useful in
treating B cell malignancies.
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4.4. FIGURES

Figure 4.1. Myh11-Cre does not consistently target vascular smooth muscle in the bone
marrow. A. Representative photomicrographs showing Myh11-Cre-targeted cells (red) and
smooth muscle actin staining (green) in small intestine (left panel) and aorta (right panel). B.
Representative photomicrographs showing Myh11-Cre-targeted cells (red) and smooth muscle
actin staining (green) in bone marrow. Scale bar: 100 µm.
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Figure 4.2. Lentiviral expression of CXCL12 in hematopoietic cells is not sufficient to rescue
bulk bone marrow CXCL12. A. GFP chimerism corresponding to lentivirally-transduced cells in
the peripheral blood of transplanted mice of the indicated genotype and viral infection 6 weeks
post-transplant. B. CXCL12 ELISA showing the amount of CXCL12 protein in the bone marrow
of mice of the indicated genotype transplanted with hematopoietic cells of the indicated virus
infection.
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